| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
PHYSIOLOGICAL REVIEWS Vol. 78 No. 4 October 1998, pp. 921-947
Copyright ©1998 by the American Physiological Society
Amgen, Thousand Oaks, California; and Department of Medicine and the Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana
I. INTRODUCTION
II. BRIEF HISTORY OF DISCOVERY OF PHOSPHOLAMBAN
III. PURIFICATION AND STRUCTURE OF PHOSPHOLAMBAN
IV. PHOSPHOLAMBAN GENE STRUCTURE, EXPRESSION, AND REGULATION
V. MECHANISM OF CALCIUM PUMP REGULATION IN SARCOPLASMIC RETICULUM
VI. PHOSPHOLAMBAN PHOSPHORYLATION AND FUNCTION IN INTACT SYSTEMS
VII. PHOSPHOLAMBAN EXPRESSION IN HUMAN HEART FAILURE
VIII. CONCLUDING REMARKS
REFERENCES
 |
ABSTRACT |
|---|
 Top References
|
|---|
Simmerman, Heather K. B., and Larry R. Jones. Phospholamban: Protein Structure, Mechanism of Action, and Role in Cardiac Function. Physiol. Rev. 78: 921-947, 1998. 
A comprehensive discussion is presented of advances in understanding the structure and function of phospholamban (PLB), the principal regulator of the Ca2+-ATPase of cardiac sarcoplasmic reticulum. Extensive historical studies are reviewed to provide perspective on recent developments. Phospholamban gene structure, expression, and regulation are presented in addition to in vitro and in vivo studies of PLB protein structure and activity. Applications of breakthrough experimental technologies in identifying PLB structure-function relationships and in defining its interaction with the Ca2+-ATPase are also highlighted. The current leading viewpoint of PLB's mechanism of action emerges from a critical examination of alternative hypotheses and the most recent experimental evidence. The potential physiological relevance of PLB function in human heart failure is also covered. The interest in PLB across diverse biochemical disciplines portends its continued intense scrutiny and its potential exploitation as a therapeutic target.
The molecular mechanisms regulating myocardial contractility through After the discovery of PLB, early reviews described the apparent role of PLB in regulation of calcium transport across the sarcoplasmic reticulum and sketched a complex protein structure (3, 39, 111, 191, 208, 210, 216, 217). Interest in PLB grew as structure-function details were revealed experimentally, which suggested that PLB might itself exhibit channel activity (7, 115, 193), and recent compilations have updated descriptions of PLB structure (31, 37a, 197a). Other recent summaries have focused on the role of PLB in the regulation of myocardial function by catecholamines (36, 59, 95, 114, 200, 207) and the role of PLB in skeletal and smooth muscle (137). The present review attempts to provide a complete historical perspective of PLB structure and function studies as a framework for understanding better the current approaches to revealing the properties and physiological role of this unique protein. Phospholamban was first identified in cardiac microsomes as a 22-kDa protein serving as the principal substrate for cAMP-dependent protein kinase (125, 213, 247). Lower-molecular-mass forms of phosphorylated PLB (7-12 kDa) were later identified in sarcoplasmic reticulum vesicles (15, 87, 245) and shown to be interconvertible with the 22-kDa form; boiling in SDS (124) or treatment with Triton X-100 (128) caused dissociation of the 22-kDa form into the low-molecular-weight forms, which could be reassociated to the 22-kDa form by freezing overnight (124). These observations led to an early proposal that PLB was a homodimer (128). Other intermediate forms of phosphorylated PLB were subsequently observed in sarcoplasmic reticulum, prompting descriptions of PLB as a heterotrimer (140) or a homotetramer (105). The development of a method to purify PLB in the dephosphorylated form, however, ultimately permitted determination that PLB is a pentamer of identical subunits (240). More recent studies of purified PLB and mutagenic variants have revealed considerable detail of PLB structure and subunit interactions, summarized in section III. In part because of the complexity of PLB structure, its precise function and mechanism of action have been elusive. Phospholamban was originally implicated in the regulation of calcium transport across the cardiac sarcoplasmic reticulum by the correlation of cAMP-induced stimulation of calcium transport by the Ca2+-ATPase, with the predominant phosphorylation of PLB by the cAMP-dependent protein kinase (110, 125, 213, 215). Because of its role as the principal substrate of cAMP-dependent protein kinase in cardiac sarcoplasmic reticulum vesicles, Tada et al. (212, 213) named the protein phospholamban, meaning "phosphate receptor." The level of calcium transport stimulated by cAMP-dependent mechanisms was commensurate with the degree of phosphorylation of PLB (212, 217). Phospholamban was also found to be the principal substrate of an endogenous myocardial calcium/calmodulin-dependent protein kinase (128) and is one of the few proteins avidly phosphorylated in sarcoplasmic reticulum by both cAMP-dependent and calcium/calmodulin-dependent protein kinases (16, 89, 106). The enhanced rate of calcium transport stimulated by calcium/calmodulin-dependent protein kinase parallels the activity of the Ca2+-ATPase and phosphorylation of PLB (174). Phosphorylation of PLB by the cAMP-dependent and calcium/calmodulin-dependent protein kinases occurs independently and additively (16, 77, 128, 209, 240), as does the concomitant stimulation of calcium transport and ATPase activity (116, 179, 209), although one study found nonadditivity in stimulation of ATPase activity (32). Cardiac sarcoplasmic reticulum also contains an endogenous phosphatase activity, which is capable of reversing these phosphorylation effects (108, 117, 118, 147, 214, 240). The concentration of calcium required for half-maximal activation of the calcium pump and calcium transport (KCa value) is decreased by ~50% after cAMP-dependent phosphorylation of PLB (65, 215) and further decreased by additional phosphorylation of PLB by calcium/calmodulin-dependent protein kinase (116, 209). Although the decrease in KCa produced by phosphorylation may not seem very impressive upon first consideration, in actuality, at low ionized calcium concentration (submicromolar calcium concentration) where the calcium pump is marginally active, phosphorylation of PLB by protein kinases induces a substantial increase in calcium transport to levels increased by fourfold or greater (65, 190, 213). These results suggested that PLB phosphorylation increases the apparent affinity of the Ca2+-ATPase for calcium (208). Several other lines of evidence suggested that dephosphorylated PLB acts as an inhibitor of the Ca2+-ATPase and that phosphorylation releases the inhibition (78, 107, 202). Sites of interaction between PLB and the Ca2+-ATPase and the functional consequences of this interaction have been examined with the recent aid of mutagenesis techniques and the development of practicable expression systems, described in section V. The physiological role of PLB in cardiac health and disease has been the source of much speculation. Phospholamban clearly is a mediator in the regulation of myocardial function by catecholamines through the cAMP cascade. Consistent with this, PLB is present in slow skeletal muscle as well as cardiac muscle, which both exhibit cAMP-dependent stimulation of calcium transport, whereas PLB has not been identified in fast skeletal muscle, which lacks this response pathway (92, 109). By use of antibodies to the purified protein, PLB has also been detected in microsomal membranes prepared from several types of smooth muscle (180), including membranes prepared from large and medium-sized arteries (35, 42, 44, 178), although the highest content nevertheless remains in the heart. A more widespread distribution of PLB in smooth muscle suggests it may play a broader regulatory role in the cardiovascular system. For example, in PLB knockout mice, tissue contractility is affected in both cardiac (144) and smooth muscle (123a). Recent development of sensitive immunological techniques, viable reconstitution methods, and cell expression and transgenic model systems has enabled testing of current hypotheses regarding the physiological function of PLB, described throughout this review. Identification and structural analysis of PLB in heart were initially problematic because of the difficulty in isolating the purified membrane protein. For definitive localization of PLB, reproducible methods for preparation of purified sarcolemmal and sarcoplasmic reticulum vesicles were required (87), and before their implementation, the use of impure and incompletely characterized membrane fractions contributed to confusion regarding the identification, localization, and role of PLB in regulating intracellular calcium flux. Part of the confusion came in distinguishing PLB from a 15-kDa sarcolemmal phosphoprotein also present in crude cardiac membrane preparations (86), which was subsequently purified, cloned, and named phospholemman (173). In highly purified preparations of cardiac sarcolemmal and sarcoplasmic reticulum vesicles, the highest content of PLB was found in free and junctional sarcoplasmic reticulum vesicles, and the lowest amount in the sarcolemmal fraction (90, 150, 176). Furthermore, immunoelectron microscopic studies on the subcellular localization of PLB in intact cardiac muscle, using two different antibodies highly specific for PLB, demonstrated a uniform distribution of PLB throughout the sarcoplasmic reticulum and absence from the surface sarcolemma and t tubules (93, 94). Thus an early proposal that PLB was a component of the sarcolemmal slow calcium channel, i.e., "calciductin" (23, 72, 183), or another unique sarcolemmal protein (47, 72, 80, 124, 138) was subsequently shown to be unlikely (150, 176) but reflective of the general difficulty in obtaining pure membrane fractions and the more specific problem in identification and isolation of purified authentic PLB (99). Contributing to this, earliest purification efforts generally used harsh conditions of organic solvents or strong detergents to solubilize PLB, which usually was phosphorylated to aid in monitoring the purification (14, 23, 25, 30, 67, 106, 129, 130). The "proteolipids" isolated from these efforts exhibited acidic isoelectric points but disparate amino acid compositions, suggesting that homogeneous preparations of authentic PLB were probably not achieved. An additional claim that PLB remained strongly associated with the Ca2+-ATPase after detergent solubilization (129, 130) was not universally observed (78, 121). A breakthrough in the characterization and understanding of PLB came with the purification of the dephosphorylated protein by conventional chromatographic methods in sufficient amounts for further detailed biochemical studies (79, 240). Jones and co-workers (90, 91, 240) purified PLB by sulfhydryl group affinity chromatography after solubilization of the protein from canine cardiac microsomes using the zwitterionic detergent Zwittergent 3-14. Tada and co-workers (79, 211) purified the protein from canine cardiac microsomes in the nonionic detergent C12E8 using a combination of size-exclusion and ion-exchange chromatographies. The isolated PLB protein (90, 91) differed in two major respects from the proteolipids characterized previously: it was basic (pI = 10, dephosphorylated; pI = 6.7, phosphorylated) not acidic (pI = 3.7-4.1) (14, 15, 129, 130), and it was cysteine rich (6 mol%) not cysteine deficient (14, 129, 130). The cysteine residues were not disulfide bonded (193). Electrophoretic analysis of highly purified PLB demonstrated a series of phosphorylation-induced mobility shifts in SDS polyacrylamide gels that was additive upon simultaneous phosphorylation by cAMP-dependent and calcium/calmodulin-dependent protein kinases, providing evidence for a protein structure of multiple identical phosphorylatable subunits (240). Confirming this, electrophoretic studies of sarcoplasmic reticulum membranes phosphorylated in vitro (32, 57, 77, 81, 82) and in vivo (175, 242) were consistent with the notion that PLB monomers could be simultaneously phosphorylated in situ by both kinases. Upon phosphorylation by cAMP-dependent protein kinase, PLB exhibited a dramatic change in pI, from 10 (dephospho) to 6.7 (phospho) (90). This large change in charge is undoubtedly important to the function of PLB and its ability to reversibly regulate the calcium pump. Proteolytic cleavage, peptide mapping, and phosphoamino acid analysis of purified PLB supported the model of PLB as a pentamer (240) of identical low-molecular-weight subunits, each of which can be phosphorylated at distinct sites by cAMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase (241). A largely hydrophobic, protease-resistant domain on each subunit appeared to be responsible for anchoring PLB in the sarcoplasmic reticulum membrane and for holding the multiple subunits together, and a smaller protease-sensitive domain on each subunit contained all of the phosphorylation sites. Only serine was phosphorylated by cAMP-dependent protein kinase, whereas calcium/calmodulin-dependent protein kinase phosphorylated exclusively threonine (193, 241), contradicting early observations from less pure preparations that PLB is phosphorylated only at serine residues (128, 130). An early structural model of PLB (193), based on the partial amino acid sequence and the biochemical characterizations described above, is depicted in Figure 1.
The cGMP-dependent protein kinase phosphorylates cardiac and smooth muscle PLB in vitro on the same serine as the cAMP-dependent protein kinase (24, 71, 179), and experiments with intact cardiac myocytes (185) and smooth muscle cells (35, 98, 186) demonstrate that PLB is phosphorylated in vivo by cGMP-dependent mechanisms, although conflicting results with intact cells were obtained in one study (71). Calcium/phospholipid-dependent protein kinase C was also reported to phosphorylate PLB in vitro on the same protease-sensitive peptide as the other kinases (80, 163). However, PLB is not an efficient in vitro substrate for protein kinase C compared with cAMP- and calcium/calmodulin-dependent protein kinases, and the localization of this protein kinase activity to cardiac sarcolemma and its absence from sarcoplasmic reticulum casts doubt on the physiological relevance of protein kinase C phosphorylation of PLB (176). Wegener et al. (242) found no evidence for in vivo PLB phosphorylation by protein kinase C in perfused guinea pig hearts, an observation also demonstrated in intact guinea pig hearts (40), in rat cardiac myocytes after administration of phorbol ester (63), and in perfused rat hearts after Phosphorylation of PLB pentameric subunits by cAMP-dependent protein kinase occurs by a random mechanism (131), whereas results of gel-mobility shift analysis have been interpreted to suggest that calcium/calmodulin-dependent phosphorylation proceeds by a cooperative mechanism (82). Cross-linking and affinity-labeling experiments have suggested that PLB binds calmodulin (139), that calmodulin binding to PLB is inhibited by prior phosphorylation of PLB by either cAMP-dependent or calcium/calmodulin-dependent protein kinases (156), and that calmodulin binding may be a prerequisite for PLB phosphorylation by the calcium/calmodulin-dependent protein kinase (198). However, the role of this proposed calmodulin binding to PLB in the functional regulation of the Ca2+-ATPase by PLB is unsupported, and the binding of calmodulin to PLB is marginal compared with the major calmodulin binding protein of the sarcoplasmic reticulum, the ryanodine receptor (189). Endogenous phosphatases of the sarcoplasmic reticulum are nondiscriminatory in their ability to dephosphorylate the serine phosphorylated by cAMP-dependent protein kinase and the threonine phosphorylated by the calcium/calmodulin-dependent kinase (118, 147), although dephosphorylation at the cAMP-dependent site was suggested to occur by a cooperative mechanism (131). Early studies noted that phosphatidylinositol potentiated phospholamban phosphorylation by cAMP-dependent protein kinase (203) and that the phosphorylation of phosphatidylinositols by cAMP-dependent protein kinase occurred concurrently with PLB phosphorylation (83). However, these findings have not been confirmed, and a role for phosphatidylinositol or other specific phospholipids in the PLB regulatory pathway has not been identified. Amino acid sequence analysis of purified PLB after phosphorylation revealed that the serine and threonine residues phosphorylated uniquely and exclusively by cAMP-dependent and calcium/calmodulin-dependent protein kinases, respectively, are adjacent (193), refuting an early proposal espousing two distinct PLB polypeptides of slightly different molecular weights, each bearing a single site phosphorylated by one or the other protein kinase (25). Elucidation of the complete PLB primary structure by Fujii and co-workers by amino acid sequencing (49) and cloning of the cDNA (53) firmly established the molecular mass of each monomer to be 6,080 Da and confirmed the hypothesis that oligomeric PLB is a pentamer of 5 identical subunits (90, 240, 241), each containing only 52 amino acids (Fig. 2). Serine-16 and threonine-17 were identified as the residues phosphorylated by cAMP-dependent protein kinase and by calcium/calmodulin-dependent protein kinase, respectively (53, 193). Consistent with earlier experimental evidence that PLB was composed of two domains (241), analysis of the PLB sequence by hydropathic profiling and secondary structure predictive algorithms (53, 193) suggested a structure comprised of a hydrophilic, cytoplasmically oriented amino-terminal domain containing the phosphorylation sites and a carboxy-terminal hydrophobic domain anchoring the protein in the membrane (Fig. 2). The hydrophobic region was predicted to form a helix sufficiently long to traverse the sarcoplasmic reticulum membrane and, when assembled into the pentameric oligomer, to form a domain resembling a channel structure (193) (Fig. 1). The sequence of PLB from several species is shown in Figure 2, illustrating the highly conserved primary structure of the protein.
Determination of the amino acid sequence of PLB (49, 53, 193) promoted the development of more specific methods for its detection, quantitation, and characterization, including the development of specific cDNA and antibody probes. Alternative methods for preparation of PLB were soon reported thereafter. Immunoaffinity chromatography from deoxycholate-solubilized sarcoplasmic reticulum vesicles yielded PLB that exhibited pentamers in SDS (201), like the protein purified from Zwittergent 3-14 (90) or C12E8 (49), supporting the belief that oligomeric assembly is an inherent property of PLB and is independent of the method of PLB preparation. Knowledge of the PLB sequence enabled access to recombinant methods for its de novo synthesis. In vitro translation of mRNA transcribed from cDNA of the PLB sequence was used to confirm that PLB spontaneously forms pentamers both in the presence and in the absence of microsomes (33, 194). Interestingly, PLB expressed in Escherichia coli caused cell lysis, restricting the utility of this synthetic route, but strengthening the hypothesis that PLB may exhibit pore-forming activity (33, 115). With the use of mass spectrometry and direct sequence analysis to monitor purification efforts, a successful protocol was eventually developed for isolation of authentic PLB in organic solvents (18); the PLB was phosphorylatable with cAMP-dependent protein kinase and formed pentamers in SDS, indicating retention of these "functional" properties. However, aggregation was a problem after purification of PLB with use of organic solvents (18). Although by the original method for purification of PLB a considerable amount of protein could be isolated sufficient for detailed biochemical studies (3-5 mg of highly purified PLB were isolated routinely from sarcoplasmic reticulum vesicles prepared from 18-20 dog hearts; Refs. 90, 91), it is now possible to purify PLB by monoclonal antibody affinity chromatography after expression of the protein in insect cells using the baculovirus cell expression system (181). By this method, 15-20 mg of recombinant wild-type or mutant PLB are typically isolated at a time (181, 182, 194). The recombinant protein behaves identically as the native protein: it is isolated as a pentamer with oligomeric mobility forms indistinguishable from the natural protein (Fig. 3) and retains the phosphorylation-induced mobility shifts, it exhibits a blocked amino terminus, and it reconstitutes functionally with the cardiac or skeletal muscle calcium pumps like native PLB (181, 182). Recently, PLB has been prepared by complete chemical synthesis using standard peptide synthesis and purification methods in organic solvents and exhibited biochemical characteristics similar to native PLB (152, 235). The ready availability of large quantities of recombinant and synthetic PLB should greatly facilitate future studies directed toward its biochemical and structural characterization.
The secondary structure of PLB as well as the amount and type of short-range interactions forming helix or Given the apparent instability of structure in the PLB cytoplasmic domain, it should perhaps not be surprising that phosphorylation effects on secondary structure have so far been inconclusive. Circular dichroism measurements of the cytoplasmic domain in organic solvents suggested that phosphorylation results in a decrease in helicity by 6% (221), 11% (70), and 33% (160), although in aqueous solution little (10% decline) (220) or no change in structure (10, 196, 221) is attributable to phosphorylation. Results from nuclear magnetic resonance in trifluoroethanol suggest an unwinding of helix at residue 12 and the following residues after phosphorylation (160), but in aqueous buffers, the formation of a salt bridge between arginine-14 and serine-16(P) may induce or stabilize a nascent helix in this region (160, 177). The transient and inducible nature of the cytoplasmic PLB structure, which is sensitive to its environment, may partly account for these discrepant experimental observations concerning which specific residues in this peptide adopt a helical configuration and how phosphorylation may affect the secondary structure. The propensity of PLB monomers to self-associate forming an oligomeric structure was recognized using electrophoretic analysis soon after its discovery. However, deviation from ideal electrophoretic behavior often seen with membrane proteins and low-molecular-weight peptides caused early confusion regarding the number and nature of PLB subunits that associate. Subsequently, gel filtration in SDS with postcolumn detection by laser light scattering (238) supported the model of a pentameric quaternary structure deduced from the electrophoretically resolved oligomeric mobility forms (Fig. 3 showing pentameric through monomeric mobility forms) and from the 10 discrete phosphorylation-induced mobility shifts in the pentamer after graded phosphorylation by cAMP- and calcium/calmodulin-dependent protein kinases (32, 77, 240, 242) (Fig. 4). The preferred assembly into pentamers was also suggested by gel filtration in deoxycholate and by sucrose density centrifugation in the presence or absence of octyl glucoside (61). The agreement in this latter hydrodynamic study may be serendipitous, however, because no attempt was made to correct for detergent binding to the protein. Although chemical cross-linking experiments failed to detect higher order oligomers than dimers of PLB in sarcoplasmic reticulum vesicles (251), the observation that purified PLB or the hydrophobic domain of PLB residues 26-52 displays conductance properties classically attributed to channels suggested that PLB at least transiently forms a pentameric pore structure in membranes (115). Recent experiments using electron paramagnetic resonance spectroscopy on lipid-reconstituted recombinant PLB have verified that it is present primarily as a pentamer in the lipid bilayer (34). However, in the dephosphorylated form, a substantial fraction of monomers is also present, contributing ~20% of the total PLB protein and giving a molar ratio of ~1:1 for pentamers to monomers. Remarkably, the proportion of pentameric PLB species in the membrane approaches 100% after PLB phosphorylation. This suggests that electrostatic repulsion between the cytoplasmic head groups of PLB may inhibit pentamer formation. Phosphorylation of PLB, which changes the isoelectric point from 10 to 6.7 (90), may reverse this charge repulsion and allow complete oligomerization. This change in oligomeric size due to phosphorylation is not detected under SDS-PAGE or high ionic strength conditions, probably because the electrostatic effects are screened by SDS or high concentrations of ions (34).
The specific residues that interact to create the pentameric structure of PLB are confined to the carboxy-terminal hydrophobic domain (8, 193, 194, 241). To probe the involvement of polar residues within this domain in the formation of PLB quaternary structure, site-specific mutants of PLB were studied by Fujii et al. (51), who first expressed the protein in mammalian cells. Replacement of the polar glutamine residues at sequence positions 22, 23, 26, and 29 and the asparagine residues at positions 27 and 30 with either alanine or the respective acid forms of each amide residue had no effect on the thermal stability of the PLB pentamer as monitored by electrophoresis, indicating their lack of involvement in PLB oligomers (51). However, mutation of the cysteines at positions 36, 41, and 46 to serine, alanine, or phenylalanine indicated that PLB quaternary structure is sensitive to changes at these sites and is most intolerant of changes in cysteine-41 (51). Pentamer formation and stability decreased as the size of the substituted side chain increased, implicating a steric or surface area-related component in disruption of the oligomeric interactions. With the design of other mutagenesis experiments to focus on the role of PLB hydrophobic residues, it was noted that the heptad repeat of leucines at positions 37, 44, and 51 conforms to the structural motif of a leucine zipper, and the further heptad repeat of isoleucines at positions 40 and 47 renders an overall 3-4 residue repeat spacing characteristic of a coiled coil (195). Specific replacement of any of these individual residues with alanine prevented PLB pentamer formation, indicating their essential involvement in the oligomeric assembly (194). Experiments to probe the sensitivity of the PLB pentamer to individual mutations of other nonzipper residues to alanine enabled mapping of the surface orientations of these sequence positions. The quaternary structure of PLB was thus proposed to be a coiled-coil symmetric structure containing a central pore defined by the specific hydrophobic surface interactions of the five stabilizing leucine/isoleucine zippers, which are oriented to the interior and form the backbone of the pentamer (194, 195) (Fig. 5).
An alternate approach by Arkin et al. (8) used saturation mutagenesis of a chimeric protein construct in which Staphylococcal nuclease (a monomeric soluble domain) was fused to the amino terminus of PLB. It was found that the chimeric fusion protein formed pentamers like native PLB and was independently observed that the mutationally sensitive residues of PLB forming the oligomers lined up on faces of a 3.5-residue/helical turn coiled-coil configuration (8). To map the orientation of the cysteine sulfhydryls in the membrane-embedded domain of PLB, exchange of the sulfhydryl S-H to S-D was examined with a synthetic peptide composed of residues 25-52 of PLB, which was purified from organic solvents (9). The results supported the model of a stable, membrane-associated oligomer of PLB and suggested that only one sulfhydryl, that of cysteine-41, is able to exchange and thus is oriented toward the outer surface of the structure where it may exchange with water diffused in the bilayer. However, the pentameric association of the peptide was not verified in this study (9). Although PLB models generated from the two surface mapping studies agree on the general orientation of the PLB helices (37a), the model interpreted from the sulfhydryl exchange results suggests that four of the seven PLB helical faces are occluded from lipid exposure (9), whereas the model derived from the specific mutagenesis results suggests that only two helical faces, those of the leucine/isoleucine zippers, are completely unavailable for lipid interaction (194). A recent detailed study, which uses a computational method in combination with computerized analysis, has compared the merits of the two models by critically assessing the role of the leucine/isoleucine zipper region in pentamer stability (64a). High-resolution methods such as crystallography and nuclear magnetic resonance will ultimately be needed to resolve the fine details of PLB quaternary structure, however (37a). Indeed, recently, the crystal structure has been determined for a five-stranded coiled-coil protein, the cartilage oligomeric matrix protein (149), which bears a remarkable similarity to the model proposed for PLB (194, 195). The PLB gene is highly conserved and present in single copy in the genome of mammalian (54, 85, 144) and avian (227) species. One exon encodes the 52-amino acid protein in the rabbit (54), rat (85), mouse (60a, 144), and chicken (227). An unusually long intron is present in the 5'-untranslated region in all these species. A highly conserved region within the first 113 base pairs of the 5'-flank of the PLB gene was found in mammals (85). Potential consensus cis-promoter elements similar to known muscle-specific promoters have been identified (54, 85, 227), and a recent study suggests that a GATA-4 motif may be especially important for cardiac-specific PLB gene expression (60a). In this same study (60a), enhancer regulatory elements were located at least 600 base pairs upstream from the transcription start point, and evidence was presented that the PLB intron may contain repressor elements capable of modulating PLB gene expression. In humans, the PLB gene has been mapped to chromosome 6.q22.1, distant from the cardiac Ca2+-ATPase gene, which is located on chromosome 12 (54, 172a). Thus transcriptional regulation of the calcium pump and its regulator, PLB, are not controlled by a simple, spatially linked mechanism. Only a single type of PLB molecule has been found in all species examined; there do not appear to be any alternative splice isoforms of the protein. The remarkable conservation of the PLB sequence is evident in Figure 2. Phospholamban gene expression has been probed in various tissue sources from several species. Messenger RNA of different sizes has been isolated from the dog (229), rabbit (50), pig (231), and chicken (227), most likely representing use of different poly(A) attachment sites in the 3'-untranslated regions. Among mammalian, avian, amphibian, and fish species, protein expression levels of PLB and calcium transport activity were compared, and the results provided an early suggestion that the proportion of PLB and Ca2+-ATPase expressed may not be constant, but may differ depending on the species source (244). In this study, however, the existence of PLB in hearts of lower vertebrates (frog and carp) was suggested only by phosphorylation and was not verified with use of a specific antibody or by other more direct methods. Isolation and comparison of PLB cDNAs from mammalian smooth muscle and cardiac tissue demonstrate the identical nucleotide sequence (76, 231), as expected for the presence of a single-copy gene (54, 85, 144). However, expression of the gene is tissue specific, with less PLB mRNA seen in smooth muscle than in cardiac muscle (42, 76), consistent with immunological probes of PLB tissue distribution and protein expression levels (42, 180) and by relative PLB phosphorylation levels in aortic versus cardiac tissue (24, 239). Disparate expression of PLB relative to the Ca2+-ATPase has also been observed in pig smooth muscle tissues (42). Stomach, ileum, pulmonary artery, and aorta from pig all showed comparable levels of calcium pump mRNA and protein (SERCA2 isoform), whereas PLB mRNA and protein varied over a 12-fold range, with depleted amounts of PLB detected in the pulmonary artery and aorta (42). However, much more PLB was detected in canine and bovine aorta (41, 180). It is obvious from these results that expression of the cardiac calcium pump (SERCA2) and PLB are not always coordinately regulated, as further exemplified from results of hormonal treatments, as discussed below. Three Ca2+-ATPase genes (SERCA1, SERCA2, and SERCA3) exist encoding the 100,000-kDa sarcoplasmic reticulum/endoplasmic reticulum calcium pumps in intracellular membranes (21). In heart and slow-twitch skeletal muscle, only the SERCA2a pump is expressed significantly (137), which originates as an alternative splice variant from the SERCA2 gene and is the main isoform coupled to PLB. In smooth muscle, the SERCA2b isoform is mainly expressed, which is identical to SERCA2a except for the presence of an extended tail of 49 amino acids replacing the carboxy terminal four residues of SERCA2a. In fast-twitch skeletal muscle, the SERCA1 gene is predominately expressed, whereas the SERCA3 gene product is found at low levels in a wide variety of tissues (21, 137). SERCA1a is the predominant alternative splice isoform of the calcium pump expressed in adult fast-twitch skeletal muscle (21). Phospholamban expression can be induced in fast-twitch skeletal muscle, a tissue devoid of PLB (92, 109), by chronic low-frequency stimulation (19, 126), which changes the phenotype of the muscle from fast twitch to slow twitch. Under these conditions, the skeletal muscle isoform of the Ca2+-ATPase (SERCA1a) is concurrently switched to the isoform found in slow-twitch and cardiac tissues (SERCA2a) (19, 126). With the use of quantitative immunoblotting with specific antibodies, proportions of PLB and SERCA2a were found to be nearly identical in canine cardiac, slow-twitch, and chronically stimulated fast-twitch tissues (20). However, functional analysis of the regulatory effect of the PLB on the Ca2+-ATPase in each type of tissue indicated that PLB is not tightly coupled to the calcium pump in the slow-twitch or chronically stimulated fast-twitch muscle, in that calcium transport and Ca2+-ATPase activity in sarcoplasmic reticulum vesicles from these tissues were poorly stimulated (2-fold or less) by a monoclonal antibody that reverses the PLB inhibitory effect (20). A recent analysis of the time course of mRNA and protein expression during chronic stimulation of fast-twitch skeletal muscle indicated a close correspondence between the appearance of PLB mRNA and PLB protein, whereas induction of the SERCA2a protein lagged behind expression of its mRNA (68). A follow-up study indicated that the transcription rates of the SERCA2 and PLB genes in chronically stimulated fast-twitch skeletal muscle are discoordinately regulated (68a). Incompletely understood is why some tissues, viz. slow skeletal muscle, (20) and certain smooth muscles (178, 239), exhibit ratios of expression of PLB to SERCA2 that are equal to those present in heart, but nonetheless have poor functional coupling between the two proteins (230). Other functions for PLB in these tissues have been proposed, but none has yet been demonstrated. There is one report that PLB may regulate a chloride channel in sarcoplasmic reticulum (37). Recent results with PLB knockout mice (136a, 196b) and transgenic mice overexpressing PLB in skeletal muscle (196a) suggest that PLB plays a physiological role in skeletal muscle, but its regulatory effects on the calcium pump and contractility in this tissue nevertheless remain much less impressive than that in cardiac muscle. Fortunately, several cell culture systems useful for expression of recombinant PLB and SERCA2, employing COS-1 cells (224, 231), HEK-293 cells (223), and Sf21 insect cells (11, 12), maintain efficient coupling between the two expressed proteins and are now utilized widely for investigational purposes. Discoordinate regulation of the expression of PLB and the Ca2+-ATPase in heart is exemplified from results of thyroid hormone treatment. Treatment of rabbits with thyroid hormone resulted in a 67% elevation in Ca2+-ATPase mRNA and a 39% decrease in PLB mRNA levels, whereas hypothyroidism evoked a 49% reduction in Ca2+-ATPase mRNA with no effect on the level of PLB mRNA (165). Similar trends in response to thyroid hormone have been obtained in rats by monitoring PLB and Ca2+-ATPase mRNA levels (104) or by measuring the PLB and Ca2+-ATPase proteins directly (13, 113). In these latter three studies, calcium uptake into cardiac sarcoplasmic reticulum was increased with hyperthyroidism and decreased with hypothyroidism, as originally observed by Suko (199). With hyperthyroid rat hearts, the rate of cardiac relaxation was increased, and in sarcoplasmic reticulum vesicles isolated from these hearts, the apparent affinity of the calcium pump for calcium was also increased, as predicted from the decreased levels of PLB expression found relative to expression of the calcium pump (13, 113). Therefore, it seems likely that alteration of the ratio of PLB to SERCA2a with the thyroid hormone state produces significant mechanical effects, but changes in levels of other proteins including ratios of myosin isoforms (113a) should also be considered as accounting for contractile effects. Observations of the effects of thyroid hormone on heart have led to the hypothesis that there may be two ways in which PLB regulates Ca2+-ATPase activity: 1) a quick-acting, short-term mechanism involving PLB phosphorylation and derepression of calcium pumping activity, and 2) a slower acting but longer term process involving a change in the molecular ratio of PLB to the Ca2+-ATPase brought about by control of gene expression (104, 113). Phospholamban gene expression during embryonic development of the heart appears to be regulated uniquely. Phospholamban mRNA has been detected in murine embryos very early in gestation at the time when spontaneous contractions are first observed (55). In chick embryos, expression of PLB mRNA is suppressed relative to cardiac Concurrent with the identification of PLB as the principal membrane substrate for cardiac protein kinases, the effect of PLB phosphorylation on calcium transport by the calcium pump (SERCA2a) of sarcoplasmic reticulum was investigated. The predominant, physiologically relevant effect of PLB phosphorylation is to increase the apparent affinity of the transport ATPase for calcium (usually expressed as a decrease in the KCa value, or the ionized calcium concentration required for half-maximal activation of the pump), with little or no effect of phosphorylation on the maximal velocity of the enzyme (Vmax) as measured at saturating ionized calcium (>1 µM) concentration. Both calcium transport and ATP hydrolysis by the pump are affected equally. This effect of PLB phosphorylation to increase the calcium affinity of the calcium pump, with little or no effect on the Vmax , has been demonstrated consistently and reproducibly by numerous investigators after phosphorylation of PLB by cAMP-dependent protein kinase (27, 32, 65, 78, 101, 107, 172, 179, 215, 246), calcium/calmodulin-dependent protein kinase (60, 172, 174), or both kinases together (32, 116, 172). Identically, monoclonal antibodies directed to the phosphorylation domain of PLB increase the sensitivity of calcium activation of SERCA2a, with little or no effect on the Vmax of the enzyme (as measured at saturating calcium concentration) (20, 22, 88, 101, 152, 159). Kirchberger and co-workers (5, 5a) have recently challenged the tenet that the main regulatory effect of phospholamban is on the calcium affinity of the calcium pump; however, the vast preponderance of data concur that the KCa value is primarily affected. Although some investigators have reported that synthetic peptides corresponding to the cytoplasmic domain of PLB have substantial inhibitory effects on the SERCA enzymes measured at saturating calcium concentration (74, 187), this effect has not been found by others (28, 88, 181, 234) and, moreover, does not appear to be functionally relevant because intact PLB does not significantly affect the Vmax of the enzyme as cited above. Direct phosphorylation of the calcium pump by calcium/calmodulin-dependent protein kinase was recently reported to stimulate the Vmax of the enzyme, independently of any involvement of PLB (223, 249). Phosphorylation of the calcium pump and Vmax effects were not observed previously by other investigators, however, and these results were recently disputed (discussed in detail by Reddy et al., Ref. 182). Mutagenesis work with recombinant SERCA2a suggested that the site of ATPase phosphorylation was serine-38 (223), but in-depth investigation of the effect of serine-38 phosphorylation revealed that any apparent Vmax effects attributed to it resulted from artifacts of incubation (172). Thus the major regulatory effect on the cardiac calcium pump is mediated by phosphorylation of PLB, and this regulatory effect is to increase the calcium sensitivity of the enzyme. As a result of studies of the types above, it was proposed that PLB in the dephosphorylated state is an inhibitor of the Ca2+-ATPase (78) and that phosphorylation of PLB removes this inhibition by increasing the enzyme's apparent calcium affinity (reviewed in Ref. 210). Subsequent studies have been directed toward elucidating the mechanism of this calcium pump suppression by PLB. Early studies assessing the mechanism of PLB action on the cardiac calcium pump used transient state analysis of ATPase activity and calcium transport to distinguish several kinetic steps in the reaction cycle (120, 218). In particular, when PLB in cardiac sarcoplasmic reticulum vesicles was phosphorylated by cAMP-dependent protein kinase, a marked increase occurred in the rate of a step associated with calcium binding to the enzyme and the rate at which the acylphosphoprotein intermediate was formed (218). However, from these types of kinetic studies one could not discern if phosphorylation of PLB directly affected the equilibrium calcium-binding affinity of the pump or, instead, caused an apparent increase in calcium affinity by accelerating a kinetic step. It was important to distinguish these two alternatives, because they have different mechanistic implications relevant to how phospholamban regulates the calcium pump. This issue was finally resolved by Inesi and co-workers (22) by measuring calcium binding to the calcium pump in cardiac sarcoplasmic reticulum vesicles directly, under equilibrium binding conditions. The measurements were made in the presence and absence of a monoclonal antibody to PLB, which removes the PLB inhibitory effect in analogy to phosphorylation (190). When calcium transport into cardiac sarcoplasmic reticulum vesicles was measured, the monoclonal antibody shifted the calcium concentration dependence for activation of transport to the left, but in the same sarcoplasmic reticulum vesicles, the antibody had no effect on the calcium affinity of the ATPase, when measured under equilibrium calcium binding conditions (Fig. 6). From these results and others, it was concluded that PLB affects the kinetics of enzyme activation by bound calcium rather than the actual calcium binding affinity (22). In support of this, it was found that under equilibrium binding conditions, the calcium affinity of SERCA2a in cardiac sarcoplasmic reticulum vesicles (containing active dephosphorylated PLB) is identical to that of SERCA1a in fast-twitch skeletal muscle sarcoplasmic reticulum vesicles, in which no PLB is present (22). Consistent with this, SERCA2a has the identical calcium sensitivity in calcium transport assays asÏSERCA1a, when expressed independently of PLB (146, 222a). It was also found that SERCA2a, like SERCA1a, has two high-affinity calcium binding sites per ATP catalytic site and that PLB does not alter this fixed stoichiometry (22). The positive cooperativity of calcium binding to SERCA is identical in cardiac and skeletal sarcoplasmic reticulum vesicles (22), which discounts the earlier proposal that PLB acts by altering calcium cooperativity (65; see also Refs. 107 and 174 in which no changes in calcium cooperativity of ATPase activation were found after phosphorylation of PLB by cAMP- or calcium/calmodulin-dependent protein kinases, respectively.) On the basis of these results, it was proposed that PLB acts by inhibiting the slow isomeric transition after binding of the first calcium to the pump, without changing the overall equilibrium constant for calcium binding (22). Phosphorylation of PLB greatly accelerates this slow transition. Future studies will continue to address the molecular mechanism by which phosphorylation of PLB accelerates the rate-limiting steps of enzyme turnover, giving an apparent increase in calcium affinity.
Suzuki and Wang (202) first demonstrated that incubation of cardiac sarcoplasmic reticulum vesicles with a monoclonal antibody recognizing only PLB increased the calcium pump activity in identical fashion as the stimulation occurring with PLB phosphorylation, confirming that PLB, and not some other phosphorylatable substrate, specifically modulates the Ca2+-ATPase. Stimulation of the ATPase by the PLB antibody also provided additional evidence that PLB, in the dephosphorylated state, acts as an inhibitor of the enzyme at low ionized calcium concentration (202). Monoclonal antibodies recognizing the cytoplasmic domain of PLB (22, 88, 152, 159) thus substitute for PLB phosphorylation in reversing the suppressor effect of PLB on the ATPase. Such antibodies have become a valuable experimental tool. For example, their use in intact cells allows selective disruption of the PLB effect free from the potential influence of phosphorylation of other components, as would occur during To achieve a better understanding of the molecular interactions between PLB and the cardiac calcium pump, attempts have been made to functionally reconstitute the two proteins using purified components. Initial efforts by Inui et al. (78) to solubilize and recompose cardiac sarcoplasmic reticulum successfully reconstituted the calcium pump activity and calcium loading rate but failed to reestablish the coupled modulatory effect of PLB phosphorylation on calcium transport; however, the reconstituted cardiac calcium pump transported calcium with threefold increased apparent calcium affinity, supporting the novel concept that PLB, when properly coupled, acts as an inhibitor of the calcium pump and that phosphorylation releases this suppression. Subsequent attempts at reconstitution of purified native PLB or synthetic PLB with skeletal muscle or cardiac ATPases achieved only limited success in that significant effects of added PLB on the Vmax of the ATPases were noted (100, 187, 205, 206, 235), which is not observed with intact cardiac membranes. In more recent studies, some progress in reconstitution has been achieved. Reddy et al. (181) successfully reconstituted recombinant PLB purified from insect cells with SERCA1a isolated from rabbit skeletal muscle sarcoplasmic reticulum. In initial studies, purified SERCA1a was utilized because this enzyme was readily available and PLB is equally effective in inhibiting SERCA1a and SERCA2a (62, 224). Successful functional coreconstitution of purified proteins into phospholipid vesicles was demonstrated by satisfying the following criteria (181): PLB inhibited the ATPase at low (pCa 6.8) but not high (pCa 5.4) ionized calcium concentration, the inhibitory effect was reversed by a monoclonal antibody to PLB, and both ATPase activity and calcium transport by the pump were inhibited by PLB, as occurs with native sarcoplasmic reticulum vesicles. Intact PLB was required to meet these criteria for a successful reconstitution. Maximal calcium pump inhibition occurred at a molar stoichiometry of approximately three PLB monomers per Ca2+-ATPase monomer in the reconstituted system (181). Neither the cytoplasmic domain of PLB (residues 1-31 acetylated at the amino terminus) nor the membrane-spanning domain (residues 26-52) resulted in successful reconstitution. On the basis of the results obtained through reconstitution, it was concluded that both the cytoplasmic and transmembrane regions of PLB are essential for normal calcium pump regulation (181). Applying the same reconstitution method, Mayer et al. (152) recently reported success using synthetic PLB and SERCA1a. In a subsequent study, Reddy et al. (182) reported on the rapid purification of the canine cardiac Ca2+-ATPase by Cibacron blue affinity chromatography and successful functional coreconstitution of SERCA2a with recombinant PLB. The same reconstitution criteria mentioned above were fulfilled and, in addition, phosphorylation of PLB by either cAMP- or calcium/calmodulin-dependent protein kinase reversed the PLB inhibition. No significant phosphorylation of the purified cardiac calcium pump by cAMP- or calcium/calmodulin-dependent protein kinase was observed, whereas PLB was readily phosphorylated, accounting for the stimulation of calcium transport at low ionized calcium concentration (182). The phospholipid vesicles reconstituted with SERCA2a retained functional and structural integrity, in that two calcium ions were transported per ATP molecule hydrolyzed, which agrees with the two calcium/catalytic site stoichiometry reported by Cantilina et al. (22) for native cardiac sarcoplasmic reticulum vesicles. Thus there is no evidence that PLB alters the coupling efficiency of the calcium pump as part of its reaction mechanism, as hypothesized in an early study (128). Although some success has been achieved in these latter reconstitution studies (152, 181, 182), there is still room for improvement in that the inhibition of SERCA provided by PLB is no greater than 50% with use of these systems. In intact cardiac sarcoplasmic reticulum vesicles, dephosphorylated PLB inhibits the calcium pump by 80% or more at the same low ionized calcium concentrations utilized. With the recent availability of milligram quantities of purified PLB and SERCA2a protein reagents, however, the efficiency of the reconstitution procedures should improve as new approaches are tried. In an earlier attempt at reconstitution of SERCA2a purified from canine cardiac sarcoplasmic reticulum, it was reported that a synthetic peptide composed of residues 1-31 of PLB (cytoplasmic domain) inhibited the Vmax of the enzyme by 36% and that a synthetic peptide containing residues 28-47 of PLB, corresponding to most of the transmembrane domain, lowered the calcium affinity (187). However, the reliability of the reconstitution system was not completely verified by the criteria defined above, and very high concentrations of peptides (100-300 molar ratios of peptides to ATPase) were required for effects, suggesting that nonspecific interactions may have occurred. Recently, another group (74, 75, 197) has reported that the cytoplasmic domain of PLB (residues 1-25) inhibits the Vmax of SERCA1a from rabbit skeletal muscle by a substantial amount (53%). In some studies (74, 75), the nonacetylated peptide was used, but in a more recent study, the acetylated peptide was required for the effect (197). The physiological relevance of all of these results remains questionable, however, because as cited above, PLB in native cardiac sarcoplasmic reticulum has no significant effect on the Vmax of the enzyme measured at saturating calcium concentration. Furthermore, using the well-characterized reconstitution system of Reddy and co-workers described above (181, 182), no significant effect of a synthetic peptide containing residues 1-31 of PLB (acetylated at the amino terminus) was found on SERCA1a (181) or SERCA2a (L. G. Reddy, D. L. Stokes, and L. R. Jones, unpublished data) activities by monitoring both ATP hydrolysis and calcium transport by the enzymes. Similar lack of effect of high concentrations of a synthetic peptide containing amino acids 1-32 of PLB on SERCA1a activity in fast skeletal muscle sarcoplasmic reticulum vesicles was noted by others (28, 234). In an earlier report, it was shown that sarcoplasmic reticulum vesicles isolated from mouse atrial tumor cardiomyocytes are essentially devoid of PLB but exhibit appreciable SERCA2a protein and calcium transport activity (88). With the use of this "natural" reconstitution system, it was shown that the cytoplasmic domain peptide (residues 2-25) of PLB had no effect on calcium transport by these cardiac sarcoplasmic reticulum vesicles (88), nor did a peptide composed of PLB residues 1-31, which was acetylated at the amino terminus like native PLB (unpublished data). Both peptides were ineffective when calcium transport was measured at both high and low ionized calcium concentrations, in line with the view that the cytoplasmic domain of PLB by itself is insufficient to inhibit the calcium pump of cardiac sarcoplasmic reticulum in any way that reflects the action of native PLB in the sarcoplasmic reticulum membrane. Attempts have been made to uncouple PLB from the Ca2+-ATPase in cardiac sarcoplasmic reticulum vesicles by different biochemical methods to better understand the nature and sites of interaction. Trypsin treatment, which degrades PLB between lysine residue 3 and arginine residue 25 (193) removing the cytoplasmic domain (241), increased the calcium sensitivity of calcium transport similar to PLB phosphorylation, suggesting that this region of PLB is involved in the inhibition of the calcium pump (73, 107). Mechanistic interpretations of these experiments, however, are complicated by the fact that trypsin also degrades the calcium pump. In an attempt to localize the cytoplasmic residues of PLB that interact with the Ca2+-ATPase, an anti-PLB monoclonal antibody that reverses the PLB inhibition was used in a competitive binding assay to map the PLB epitope to amino acids 7-16 (159). However, it is still not tested if site-specific antibodies to other regions of the cytoplasmic domain of PLB are capable of disrupting the inhibitory interaction with the Ca2+-ATPase. These results substantiate the importance of the cytoplasmic domain of PLB for reversal of the inhibition of the calcium pump by phosphorylation or antibody. In vitro reconstitution studies suggest, however, that anchoring of the cytoplasmic domain to the transmembrane region of PLB is required for effective functional coupling of PLB to ATPase inhibition (88, 181). In coexpression studies, coupling of PLB to ATPase inhibition could be achieved when severely truncated or altered cytoplasmic domains were attached to the transmembrane domain (102). These results were explained by the proposal of the existence of a circuit of regulatory interactions involving communication between cytoplasmic and transmembrane domains in both PLB and SERCA (102, 103). The large change in the isoelectric point of PLB induced by phosphorylation (90) suggests that charge-charge protein interactions may be important for the ability of PLB to inhibit the calcium pump. A change in surface membrane potential, in fact, occurs after phosphorylation of PLB and, under high ionic strength conditions, both the surface membrane potential and PLB phosphorylation effects on the apparent calcium affinity of the Ca2+-ATPase are attenuated, supporting the notion that electrostatic interactions between the cytoplasmic domain of PLB and the pump are involved in the regulatory mechanism (26). Consistent with this concept, the polyanion heparin sodium stimulates calcium uptake into cardiac sarcoplasmic reticulum vesicles to the same level as PLB phosphorylation (250), as does the application of a small concentration of negatively charged detergent (26). Tannin, a plant phenol, also stimulates the Ca2+-ATPase and calcium uptake activities by decreasing the KCa value with no effect on the Vmax , leading to the hypothesis that the acidic groups of tannin interact with basic groups of PLB to disrupt its inhibitory effect on the calcium pump (27). Another polyphenol, quercetin, reverses phospholamban inhibition of the Ca2+-ATPase in cardiac sarcoplasmic reticulum vesicles by inducing a similar increase in calcium sensitivity, and indirect evidence has been presented suggesting that quercetin interacts with the nucleotide binding site of the ATPase (154). Cross-linking experiments by James et al. (84) with a PLB photoaffinity labeling probe first indicated that lysine residue 3 of PLB in the cytoplasmic domain binds to a region of the Ca2+-ATPase just downstream of the acylphosphorylation site at aspartate residue 351. Taken together, the results suggest that PLB may inhibit the Ca2+-ATPase through electrostatic interactions involving basic residues of the PLB cytosolic domain and acidic residues of the Ca2+-ATPase near the ATP binding site and the phosphorylated aspartic acid (see mutagenesis results discussed below). The dynamic equilibrium between phospholamban pentamers and monomers in the plane of the lipid membrane also appears to be controlled by electrostatic interactions. Phosphorylation of PLB or buffers of high ionic strength promotes pentameric stability of the protein (34). Important new insights on mechanisms of calcium pump regulation have been provided through the use of cellular coexpression of recombinant PLB with SERCA enzymes. Fujii et al. (52) found that coexpression of PLB with SERCA2a in COS-1 cells lowered the calcium sensitivity of the enzyme in calcium transport assays conducted with microsomal membrane preparations, confirming by recombinant methods that PLB is an inhibitor of the calcium pump. The effect of PLB on the calcium affinity of the smooth muscle isoform of the Ca2+-ATPase (SERCA2b) has been compared with that of the cardiac isoform (SERCA2a) in another cell transfection system, and both isoforms were found to exhibit an approximately twofold decrease in apparent calcium affinity when coexpressed with PLB (230). The efficient functional coupling of PLB to SERCA2b in the transfection system (230) suggests that the relatively poor coupling between the two proteins in intact smooth muscle (178, 239) is not because of structural differences between SERCA2a and SERCA2b. With use of the recombinant coexpression system, the issue of the role of PLB in regulating the calcium sensitivity of the cardiac calcium pump vis-à-vis the Vmax of the enzyme was reassessed by Odermatt et al. (172). It was observed that phosphorylation of PLB in microsomes from HEK-293 cells coexpressing PLB and SERCA2a decreased the KCa value in transport assays by approximately twofold but had no effect on the Vmax of the enzyme at saturating calcium concentration. Similar results were observed when PLB was phosphorylated by cAMP-dependent protein kinase, by calcium/calmodulin-dependent protein kinase, or by both kinases together, and when native cardiac vesicles were analyzed in parallel experiments, the same effect on the KCa value, but not Vmax , was obtained (172). Likewise, coexpression of phospholamban with SERCA2a in Sf21 insect cells increased the KCa value obtained for activation of ATPase activity or calcium transport with no effect on the Vmax of the enzyme (12). Overexpression of PLB in cultured neonatal rat cardiomyocytes by infecting cells with PLB-encoding adenovirus also increases the KCa value with no effect on the Vmax of the enzyme (60b). Thus, with the use of the purified proteins coreconstituted biochemically (181, 182), with the use of molecular coreconstitution in cultured cells (12, 60b, 172), and with the use of native sarcoplasmic reticulum vesicles (22, 172), recent carefully controlled studies confirm the conclusion that the main functional effect of PLB is to regulate the calcium sensitivity of the SERCA2 enzyme. Mutational analyses have also been conducted with cellular coexpression systems to localize molecular domains important for PLB/calcium pump interactions. To localize residues in the Ca2+-ATPase required for functional coupling to PLB, PLB was coexpressed individually with SERCA1a, SERCA2a, and SERCA3 and found to decrease the calcium sensitivity of SERCA1a and SERCA2a, but not SERCA3 (224). In the PLB uncoupled states, SERCA1a and SERCA2a had identical high calcium affinities, but the apparent calcium affinity of SERCA3 was already low and unaffected by PLB. By analysis of SERCA2/SERCA3 chimeric proteins, regions of the Ca2+-ATPase molecule critical for the functional coupling to PLB were localized by Toyofuku et al. (224) to two cytoplasmic domains, one containing residues 336-412 (acylphosphorylation domain) and the other comprised of residues 467-762 (nucleotide binding/hinge domain). Mutagenesis experiments by Toyofuku et al. (226) further specified the essential amino acids in the acylphosphorylation domain of the Ca2+-ATPase interacting with PLB as residues 397-402 and pointed to the importance of charged side chains in the interaction. Interestingly, the SERCA2a peptide labeled by the PLB photoaffinity probe by James et al. (84) encompasses the critical ATPase interaction site later identified in the mutagenesis experiments of Toyofuku et al. (226), suggesting that lysine residue 3 of PLB in the cytoplasm may bind directly to residues 397-492 of the ATPase. Cellular coexpression of recombinant proteins has also been used to identify amino acids of PLB important for functional interaction with the cardiac Ca2+-ATPase. Phospholamban mutants coexpressed with the cardiac Ca2+-ATPase localized 13 amino acid residues between sequence positions 2-18 of PLB as important for the functional association between the two proteins (225). Point mutation of four positively charged residues, one negatively charged residue, four hydrophobic residues, two alanine residues, and the phosphorylated residues (serine 16 and threonine 17) in this region all resulted in loss of the inhibitory effect of PLB on calcium transport by the cardiac Ca2+-ATPase (225). This result emphasizes the fact that considerable structural specificity is required to maintain functional PLB coupling and that hydrophobic as well as electrostatic interactions are important. Based on these results, the authors (225) concluded that this cytoplasmic region of PLB (residues 2-18) is essential for functional association with the Ca2+-ATPase. Somewhat surprisingly, however, in a subsequent study it was observed by Kimura et al. (102) that the cytoplasmic domain of PLB could be replaced with a foreign epitope or deleted entirely with functional coupling of the PLB transmembrane domain to SERCA pumps preserved. In fact, some of the mutant PLB constructs examined, which lacked the native cytoplasmic domain, were actually stronger inhibitors of SERCA2a activity than was wild-type PLB. For example, addition of the hemagglutinin epitope to the transmembrane sequence of PLB containing residues 28-52 "supershifted" the apparent calcium affinity to values lower than those observed with native PLB. From these observations, Kimura et al. (102) proposed that the interaction between the membrane-spanning domains of PLB and SERCA2a inhibits SERCA2a by lowering its apparent calcium affinity. It was also suggested that the cytoplasmic domain of PLB is by itself not inhibitory, but instead modulates the inhibitory interactions in the transmembrane domains through a long-range coupling process (102). A puzzling but at the same time intriguing question is the role of the PLB pentamer in calcium pump regulation (31). Recent experiments (12, 103) have led to the conclusion that the PLB monomer, not the pentamer, may actually bind to and inhibit the calcium pump in the sarcoplasmic reticulum membrane. With the use of either the Sf21 insect cell system (11, 12) or HEK-293 cells (103) for coexpression of PLB with SERCA2a, changing leucine residue 37 in the leucine zipper region of PLB (Fig. 5) to alanine (L37A-PLB) depolymerized the protein in the plane of the phospholipid membrane (34), while at the same time giving a stronger inhibition of the calcium pump at low ionized calcium concentration than did coexpression of wild-type, pentameric phospholamban. Whereas coexpression of wild-type PLB with the Ca2+-ATPase increased the KCa value required for pump activation by approximately twofold, coexpression of L37A-PLB with the Ca2+-ATPase increased the KCa value by four- to fivefold (12, 103). The inhibition of the Ca2+-ATPase by L37A-PLB was shown to be reversed by addition of the PLB monoclonal antibody (12), demonstrating that the basic mechanism of inhibition of the Ca2+-ATPase by wild-type PLB and L37A-PLB was similar. From such results, it was hypothesized that PLB monomers and pentamers are in dynamic equilibrium in the lipid bilayer (34) and that PLB monomers preferentially bind to the calcium pump and inhibit calcium transport in the sarcoplasmic reticulum membrane (12, 103). Kimura et al. (103) performed scanning-alanine mutagenesis of the membrane-spanning residues of PLB and confirmed the observation (194) that leucines 37, 44, and 51 and isoleucines 40 and 47 repeating every three or four residues along one face of the transmembrane helix were the pentamer-stabilizing residues (Fig. 5). These investigators then examined the functional consequences of the PLB point mutations by coexpressing all of the mutated proteins with SERCA2a in HEK-293 cells. A remarkable cyclical pattern was noted, in that mutations on one face of the helix diminished or completely prevented inhibitory interactions with the calcium pump, whereas mutations on the opposite face of the helix activated inhibitory interactions with the calcium pump (103). Most of the mutations that enhanced inhibitory interactions with the calcium pump were the monomer-producing mutations located in the leucine/isoleucine zipper region (194) (L37A-PLB, I40A-PLB). These monomeric mutants were termed "supershifters" (102, 103) because they decreased the apparent calcium affinity of SERCA2a about twofold more effectively than did wild-type PLB. Based on these results, Kimura et al. (103) independently concluded that PLB monomers are the active species inhibiting SERCA2a in the sarcoplasmic reticulum membrane. An equally important observation of Kimura et al. (103) was the identification of several "loss-of-function" mutants of PLB (i.e., L31A-PLB, N34A-PLB, L42A-PLB) that arose from changing residues on the face of the transmembrane helix opposite from the pentamer-stabilizing face. These loss-of-function mutants were no longer able to inhibit the calcium pump effectively, suggesting for the first time the presence of essential amino acid residues in the transmembrane region of PLB that might be required for direct functional interactions with the transmembrane segments of SERCA2a. In fact, on the basis of these results (103) and those from their earlier study (102), it was concluded that the transmembrane region of PLB containing the loss-of-function mutational sites is the domain directly responsible for inhibiting the Ca2+-ATPase and lowering its apparent calcium affinity. The cytoplasmic domain of PLB, on the other hand, was proposed to modulate the inhibitory interactions in the transmembrane domain through long-range coupling (102). This would explain why the cytoplasmic domain of PLB by itself is insufficient to inhibit the ATPase (88, 181). Identification of the transmembrane residues of SERCA2a that interact directly with the putative inhibitory transmembrane helical face of PLB will be essential for a complete understanding of the mechanism by which PLB regulates the activity of the calcium pump (197a). Given the evidence that suggests that not only the PLB cytoplasmic domain but also the transmembrane domain serves a functional role beyond tethering the cytoplasmic domain to the sarcoplasmic reticulum, what are the structural details of the PLB/Ca2+-ATPase interaction? Related questions, given the model that dephosphorylated monomeric PLB is capable of interacting directly with the Ca2+-ATPase to inhibit its calcium pumping activity, involve determining the stoichiometry of PLB to the Ca2+-ATPase and, moreover, the role of oligomeric complexes of the Ca2+-ATPase itself (4) to its own function. Early indirect estimates using phosphate incorporation into both PLB and the Ca2+-ATPase for quantitation suggested a 1:1 stoichiometry of PLB pentamers to Ca2+-ATPase monomers (141, 209), but a more recent indirect study using densitometric determination of the Ca2+-ATPase concentration and mobility shift estimates of the PLB concentration indicated 0.4 mol of PLB pentamer for every mole of Ca2+-ATPase monomer (32). The concept of a fixed stoichiometry between PLB and the calcium pump in the sarcoplasmic reticulum membrane may be a "red herring," however, because of the relatively weak binding affinity between the two proteins (78, 121, 182), the ease of dissociation of the functional complex in the plane of the sarcoplasmic reticulum membrane (142, 192), the dynamic equilibrium between PLB pentamers and monomers themselves in the plane of the membrane (34), and the uncoordinated expression of the two proteins in vivo under certain conditions (104, 112). Although the true stoichiometry between PLB and the Ca2+-ATPase remains ill defined, it has been speculated that dephosphorylated PLB might restrict Ca2+-ATPase conformational freedom and thereby suppress its activity (45). In support of this hypothesis, recent experiments by Thomas and co-workers (236) using time-resolved phosphorescence anisotropy indicate that there is a distribution of oligomeric complexes of the Ca2+-ATPase in sarcoplasmic reticulum, with large stationary aggregates and slowly rotating oligomers in addition to the highly dynamic monomers. Phosphorylation of PLB increased the rotational mobility of SERCA2a as a result of a decrease in large aggregates, supporting a model in which PLB phosphorylation releases the Ca2+-ATPase from a kinetically unfavorable associated state (236), perhaps the kinetic state after the binding of the first calcium ion (22). Reciprocal aggregation (pentamer formation) of phospholamban by phosphorylation (34) with resultant deaggregation and activation of the Ca2+-ATPase (236) (Fig. 7) is consistent with the recent PLB mutagenesis studies cited above in which expression of PLB with depolymerizing mutations gives stronger inhibition of the Ca2+-ATPase than does expression of wild-type PLB (12, 103). The inhibition by PLB due to induction of Ca2+-ATPase lateral aggregation was further supported by a study of comparative molecular dynamics in mouse atrial tumor versus ventricular sarcoplasmic reticulum, which exploited the absence of PLB in the atrial membranes as a control for the ventricular membranes that contain PLB in levels similar to other mammals (237). The model proposed from these results suggests a structural and functional perturbation of the Ca2+-ATPase through electrostatic interactions with PLB that affect self-association of the Ca2+-ATPase (236, 237), resembling the general mechanism of many signal transduction processes that involve lateral association of membrane proteins (45). Mutagenesis of PLB (12, 103) combined with molecular dynamics results (34, 236, 237) suggest that the PLB monomer may be the most active species promoting Ca2+-ATPase aggregation/inactivation. Phosphorylation of PLB drives its equilibrium toward pentamers (34), which may be relatively ineffective inhibitors of the Ca2+-ATPase compared with monomers (103). Whether the pentamer by itself (in the absence of any monomers) is capable of inhibiting the Ca2+-ATPase remains to be determined. In this model of PLB interaction with the calcium pump, the pentamer in the membrane can be viewed as a reservoir for monomers (103), which dissociate from the pentamer in the dephosphorylated form (34), diffuse in the plane of membrane, and then bind to and inhibit the Ca2+-ATPase at low ionized calcium concentrations (12, 103) by an aggregation-based mechanism (236, 237) (Fig. 7). It should be pointed out that Chu et al. (29) recently overexpressed the monomeric mutant C41F-PLB in transgenic mouse ventricle and noted no stronger suppression of contractility than that achieved with overexpression of wild-type PLB. This negative result is predictable, however, because C41F-PLB, although monomeric (51, 194), is no more effective than wild-type PLB in inhibiting the calcium pump (225). This is probably because the interaction domain with the ATPase is partially perturbed with this mutation, even though the protein is monomeric (103).
Other experiments appear to provide results that conflict with the finding that dephosphorylated PLB inhibits SERCA2a by aggregating the enzyme. Studies using either time-resolved phosphorescence polarization (48) or spin-label electron paramagnetic resonance (167) have reported a decrease in the rotational dynamics of the Ca2+-ATPase associated with phosphorylation of PLB, prompting the suggestion that PLB phosphorylation actually enhances interaction between Ca2+-ATPase chains either by increasing protein-protein interactions or by altering the conformation of Ca2+-ATPase chains within a stable oligomeric state (167). These findings, however, are more consistent with PLB being an activator of the Ca2+-ATPase rather than an inhibitor, and also are difficult to reconcile with the observation that SERCA1a and SERCA2a have identical calcium affinities when PLB is not present (146) or is inactivated (22). Moreover, other recent results using time-resolved phosphorescence anisotropy to investigate the effects of the nonionic detergent C12E8 on calcium transport and molecular dynamics of the Ca2+-ATPase (192) support earlier evidence that the mechanism of PLB regulation of calcium transport involves modification of the Ca2+-ATPase oligomeric state (236, 237). To resolve these discrepancies and better define the correlation between PLB and Ca2+-ATPase oligomerization, molecular dynamics within the sarcoplasmic reticulum, and the regulation of calcium transport, further experiments will be required utilizing the latest technologies for detecting and quantitating protein-protein interactions. The intriguing pentameric quaternary arrangement of PLB subunits and its resemblance to a pore-forming structure (7, 8, 193-195) invite the question whether PLB may regulate calcium flux independent of Ca2+-ATPase activity by functioning as a channel (64a, 115). Supporting the structural model of PLB as a channel, the crystal structure of a five-stranded coiled-coil domain in the cartilage oligomeric matrix protein was recently determined (149) and bears a striking similarity to the transmembrane hydrophobic pore structure proposed for PLB (194, 195). The observed 2-6 Å internal diameter of the pore in this crystal structure and the presence of 13 water molecules distributed within the hydrophobic pore (149) provide an experimental basis to validate the plausibility of the structural model of PLB as a calcium channel. Furthermore, the regular rings of conserved glutamine residues and constrictions of the internal pore diameter caused by side chains at positions a and d of the coiled-coil residue pattern may suggest the physical basis for ion selectivity and gating (149). Single-channel recording experiments have, in fact, demonstrated calcium-selective channel behavior for PLB (115), and early attempts to directly express PLB in cell-based expression systems resulted in cell lysis (33), consistent with the ability of PLB to spontaneously form membrane pores. However, there is no evidence yet that PLB functions as a channel or passive pore in the sarcoplasmic reticulum membrane (12, 181). The good correlation of calcium uptake with changes in ATPase activity in in vitro vesicle systems supports a simple model in which the Ca2+-ATPase is regulated by phosphorylation-reversible interaction with PLB and does not require for explanation a complex model involving putative PLB calcium channel activity (10). The fact that the PLB monomer is a stronger inhibitor of calcium transport than is the pentamer (12, 103) also argues against any kind of channel activity being required for calcium pump inhibition. Nevertheless, the recent appreciation that coiled-coil structures in proteins can fulfill many functions, from molecular stalks and scaffolding (e.g., kinesin and fibrin) to dimerization and selective interaction (e.g., bZip or basic region leucine zipper transcription factors) to a dynamic hinge (e.g., influenza hemagglutinin) (37a, 145), suggests that all of the functional attributes of PLB may not yet be fully revealed. Beyond in vitro studies that indicate the important role of PLB and its phosphorylation in regulating Ca2+-ATPase activity and calcium transport across the sarcoplasmic reticulum, in vivo experiments demonstrate that PLB is a key regulator of myocardial relaxation and, as more recently demonstrated, force development as well (144). Early studies of microsomal membranes isolated from 32P-perfused mammalian hearts demonstrated that PLB is the major sarcoplasmic reticulum protein phosphorylated in intact cardiac muscle in response to The amino acid residues of PLB phosphorylated in beating mammalian myocardium in response to A vexing problem concerning PLB phosphorylation in intact muscle is that whereas PLB is readily phosphorylated in vitro at threonine-17 by calcium/calmodulin-dependent protein kinase independent of any requirement for prior phosphorylation at serine-16 by cAMP-dependent protein kinase, in intact muscle under physiological conditions, PLB is only phosphorylated significantly by agents that elevate cAMP (135). Positive inotropic agents that increase intracellular calcium concentration sufficiently high to activate calcium/calmodulin-dependent protein kinase (high extracellular calcium concentration, calcium channel agonists, From studies of the types described above, it was fairly certain that PLB was a major phosphoprotein participant in the regulation of cardiac contractility. However, because of the myriad of proteins phosphorylated in intact heart in response to In the second approach, a PLB gene knockout strategy was implemented by Kranias and co-workers (144) to create a transgenic mouse lineage completely devoid of the protein. The profound influence of PLB on contractility was then demonstrated in an elegant series of experiments using this model (reviewed in Refs. 95 and 114). Perfused hearts from PLB knockout mice had dramatic contractile changes in comparison with hearts from littermate control mice. Both rates of tension development and rates of myocardial relaxation were increased and, moreover, The PLB knockout mouse model has also proven to be useful in confirming the mechanism of action of PLB in inhibiting the Ca2+-ATPase of sarcoplasmic reticulum membranes. Calcium transport into sarcoplasmic reticulum vesicles was compared between homogenates from transgenic mouse hearts lacking PLB and homogenates from littermate controls containing normal amounts of the protein (144). Calcium uptake into sarcoplasmic reticulum vesicles from PLB-deficient transgenic mouse hearts was augmented, but only at low ionized calcium concentration, reflecting an increase in the apparent affinity of the calcium pump for calcium, with no change in the Vmax of the enzyme detected (144). In another study, the control and transgenic mouse hearts were found to contain identical levels of the calcium pump protein (29a). Thus recent in vitro and in vivo studies using state-of-the-art technologies produce consistent results demonstrating the leading role of PLB in transmitting Despite the importance of PLB to normal cardiac function, its role in the pathophysiology of human heart disease remains unknown. Two of the physiological hallmarks of human heart failure are extended calcium transients and prolonged myocardial relaxation (158), yet in one study, the magnitude of the PLB effect on calcium uptake was observed to be the same in normal versus failing heart sarcoplasmic reticulum vesicles from patients with idiopathic dilated cardiomyopathy (161). Movsesian et al. (161) showed that a monoclonal antibody to PLB stimulated calcium uptake equally well at low ionized calcium concentration with microsomes isolated from normal human hearts or with microsomes from patients with dilated cardiomyopathy. Consistent with these results, five other studies found no change in protein expression levels of either PLB or the Ca2+-ATPase in hearts from patients with end-stage ischemic or dilated cardiomyopathy (17, 46, 132, 162, 188). Earlier studies detected a decrease in PLB mRNA levels in samples from failed human hearts (6, 43), but this decrease in PLB mRNA is not associated with a decrease in PLB protein (46, 132). However, one study found that the PLB protein level was decreased slightly (18%) in hearts from patients with dilated cardiomyopathy (153), and two studies (64, 153) suggested that the protein level of the calcium pump may be decreased more substantially (36-41%). In two studies, calcium uptake (64, 188) and Ca2+-ATPase (188) activities were decreased in tissue preparations from heart failure patients, but coupling of the calcium pump to PLB was not analyzed, and there was disagreement on whether or not PLB and SERCA2a protein levels were changed. Some of the differences between laboratories are probably a consequence of the difficulties involved in obtaining adequately preserved myocardial samples from human patients. Nevertheless, all groups seem to agree that in failed human myocardium, the protein expression level of PLB is unchanged or only negligibly affected (17, 46, 132, 153, 162, 168), even though in certain animal models of heart failure the level of PLB can be downregulated substantially (184). Although the intrinsic mechanism of PLB coupling to the Ca2+-ATPase is unaltered in normal and failed human hearts (161), it remains likely that regulation of PLB phosphorylation by cAMP-dependent mechanisms (17) or other second messenger pathways (169) is perturbed, which may account partially for the diastolic dysfunction and prolonged calcium transients associated with this disease. Although much remains to be learned about the possible role of PLB in human heart failure, selective disruption of the phospholamban/calcium pump interaction is a potentially powerful target for pharmaceutical intervention to improve contractility. Phospholamban, a small protein of only 52 amino acids, has proven to be an intriguing and surprising molecule, the characterization of which traverses many fields, including membrane protein biochemistry, protein kinases and phosphatases, protein structure-function and protein-protein interactions, ion transport/ion channels, second messenger regulation of contractility and tissue excitability, and pathophysiological mechanisms involved in cardiovascular disease. The small size of PLB, its easy genetic manipulation, and its large-scale purification and chemical synthesis, coupled with the paramount physiological importance of the protein, ensure that it will be the subject of intense scrutiny across diverse fields for years to come. Phospholamban is a key mediator of
I. INTRODUCTION
Top
Next
References
-adrenergic stimulation, the familiar "fight-or-flight" response, have been the object of scientific investigations for several decades. -Adrenergic stimulation of intact hearts increases both the rate and magnitude of contraction and the rate of relaxation of cardiac muscle (228). These effects are believed to result from variations in the cytosolic calcium concentration produced by alterations in calcium fluxes across the two principal membrane systems, the sarcolemma and the sarcoplasmic reticulum (212). Since the discovery in the 1960s of the role of cAMP as a second messenger and its activation of a protein kinase, the mediation of -adrenergic effects by cAMP-dependent phosphorylation of specific proteins has been well established (58, 123, 171). In heart tissue, targets of this kinase have provided important leads in identifying key proteins of the myocardial regulatory machinery (86). Thus it has been proposed that the accelerated rate of cardiac contraction in response to -adrenergic stimulation may be caused by increased calcium influx after cAMP-dependent phosphorylation of a sarcolemmal channel protein (86, 212), whereas the accelerated rate of relaxation of -adrenergic-stimulated cardiac tissue has been suggested to result mainly from an increased rate of calcium uptake by the sarcoplasmic reticulum in response to phosphorylation of phospholamban (PLB), the principal protein phosphorylated in cardiac sarcoplasmic reticulum (208).
II. BRIEF HISTORY OF DISCOVERY OF PHOSPHOLAMBAN
Top
Previous
Next
References
III. PURIFICATION AND STRUCTURE OF PHOSPHOLAMBAN
Top
Previous
Next
References
View larger version (89K):
[in a new window]
FIG. 1.
Early structural model of phospholamban (PLB). Left: dephosphorylated pentamer. Right: phosphorylated pentamer, with 2 phosphates (P 
) incorporated per monomer. Transmembrane region is boxed with a cut-away view shown on right. Addition of +9 to numbered residues in transmembrane region gives correct sequence positions with respect to intact protein. S, serine-16 phosphorylated by cAMP-dependent protein kinase; T, threonine-17 phosphorylated by calcium/calmodulin-dependent protein kinase; ++, arginine residues 13 and 14, part of consensus sequence motif directing phosphorylation. A hypothetical conformational change in cytoplasmic domain of PLB after phosphorylation is depicted, which causes molecule to become less compact and retards its mobility on SDS-PAGE, accounting for p h o s p h o r y l a t i o n - i n d u c e d m o b i l i t y s h i f t s. [From Simmerman et al. (193).]
-adrenergic stimulation (133).
View larger version (13K):
[in a new window]
FIG. 2.
Amino acid sequences of PLB monomer from different species, deduced by cDNA cloning. Amino acid sequences are presented in 1-letter amino acid code, with residue numbers indicated in top margin. Approximate cytoplasmic and transmembrane domains are bracketed. Solid circle and box designate serine-16 and threonine-17, respectively, the 2 phosphorylated residues. Dots indicate identical residues in all isoforms. Sequences were obtained from the following references: dog (53), pig (231), rabbit (50), rat (76), mouse (55), human (54), chicken (227).
View larger version (114K):
[in a new window]
FIG. 3.
SDS-PAGE of purified recombinant PLB and canine cardiac PLB. Eleven micrograms of recombinant (Sf21 insect cell) or canine cardiac PLB were electrophoresed and stained with Coomassie blue. ±Boil indicates whether samples were boiled in SDS before electrophoresis. Numbers 1-5 designate monomeric through pentameric mobility forms of PLB. Note that boiling in SDS causes partial destabilization of pentamer. Molecular weight standards are shown at left. [From Reddy et al. (181).]
-sheet have been estimated by numerous spectroscopic studies. Circular dichroism spectroscopy of aqueous detergent solutions of PLB shows it to be predominantly helical (68-78%) (152, 196, 235). Similar results were obtained by attenuated total reflection-Fourier transform infrared spectroscopy of PLB reconstituted in phospholipid bilayers, in which PLB was 64-77% helical (10, 220). Examination by circular dichroism of the pentameric hydrophobic domain of PLB residues 26-52 in SDS showed it to be a very stable helix (67-90%) (196), a finding confirmed by attenuated total reflection infrared spectroscopy of the membrane-domain assembly reconstituted in phospholipid bilayers (73-82% helical), which also showed the membrane-spanning complex to orient predominantly perpendicular to the membrane (10, 143, 220). In marked contrast, the cytoplasmic domain of PLB studied in isolation in aqueous solutions by circular dichroism spectroscopy (70, 160, 221) or nuclear magnetic resonance (70, 160, 177) appears devoid of stable secondary structure. Rather, it appears as a flexible domain, rapidly interconverting between transient conformers (70, 177). However, the latent helix-forming potential predicted from the sequence of this domain (53) is manifested in the helix-stabilizing solvent trifluoroethanol, in which it exhibits 33-60% helix (70, 160, 221). The inducibility of helical structure in this domain is further supported by noting that the complete PLB sequence is predominantly helical in aqueous solutions (196) and is almost entirely helical in 1:1 chloroform/methanol (151). However, the transmembrane hydrophobic helix at the carboxy terminus comprises only one-half or less (
50%) of the total residues and structure of PLB (53). This suggests that other residues in the sequence must also form a helix to account for the predominantly helical structure of the overall protein. The results further suggest that anchoring the PLB cytoplasmic domain to the carboxy-terminal half of the protein alters short-range interactions to promote this helical structure.
View larger version (34K):
[in a new window]
FIG. 4.
Western blotting of PLB phosphorylated in intact guinea pig ventricles. Sarcoplasmic reticulum vesicles were isolated from ventricles exposed to 10 8 M isoproterenol for times indicated and subjected to SDS-PAGE followed by Western blotting. Eleven discrete mobility steps (0-10) of high-molecular-weight form of PLB are observed, consistent with PLB being a pentamer with 2 sites of phosphorylation per monomer. Values of 1 mM Ca2+ and 2.5 mM Ca2+ designate hearts perfused in low- and high-calcium buffers, respectively. [From Wegener et al. (242).]
View larger version (26K):
[in a new window]
FIG. 5.
Heptad repeat cartoon model of PLB monomer and pentamer. A: residues 37-52 of monomeric PLB are configured as a 3.5-residues/turn helix with positions a-g of heptad repeat circled. Leucine and isoleucine residues constituting zippers are localized to positions a and d, respectively. Changing any of these circled residues to alanine destabilizes pentamer. B: PLB pentamer. Leucine residues interacting at position a and isoleucine residues interacting at position d stabilize the pentameric quaternary structure along the length of the transmembrane helix. [From Simmerman et al. (194).]
IV. PHOSPHOLAMBAN GENE STRUCTURE, EXPRESSION, AND REGULATION
Top
Previous
Next
References
-actin transcripts, suggesting that PLB follows an independent expression program despite the presence of several putative muscle-specific promoter elements in the 5'-flanking region of its gene (222). In the developing rat heart, mRNA for the Ca2+-ATPase appears 3 days before the expression of PLB mRNA, and the mRNA of the two proteins are expressed in opposite patterns along the embryonic cardiac tube, with the calcium pump mRNA most abundant in the upstream part of the cardiac tube and the richest amount of PLB mRNA in the downstream compartments. The results suggest that there are region-specific programs of PLB and Ca2+-ATPase gene expression that may account for the functional differences in contractile properties between cardiac compartments (157). Both Mahony and Jones (148) and Szymanska et al. (204) have observed that the protein levels of PLB and SERCA2a are decreased in neonatal mammalian heart compared with adult heart, which may account in part for the decreased contractile reserve of neonatal heart and its blunted response to -adrenergic agonists.
V. MECHANISM OF CALCIUM PUMP REGULATION IN SARCOPLASMIC RETICULUM
Top
Previous
Next
References
View larger version (12K):
[in a new window]
FIG. 6.
Rates of calcium transport (left) and equilibrium calcium binding (right) to Ca2+-ATPase in canine cardiac sarcoplasmic reticulum vesicles. Activities were determined at different ionized calcium concentrations (plotted as pCa) indicated on abscissa. Triangles and circles denote values determined in presence and absence of PLB monoclonal antibody 2D12, respectively. [Adapted from Cantilina et al. (22).]
-adrenergic stimulation (190). In biochemical experiments requiring prolonged incubations, such as those measuring equilibrium calcium binding to the calcium pump in membranes, interference from phosphatase activities dephosphorylating phospholamban are obviated by use of the antibodies (22).
View larger version (48K):
[in a new window]
FIG. 7.
Cartoon model of PLB mechanism of action. Dephosphorylated PLB monomer inhibits SERCA2a (12, 103) by binding to cytoplasmic and membrane domains of pump, stabilizing enzyme in E2 conformation, and causing enzyme inhibition and pump aggregation (236). Phosphorylation of PLB reverses calcium pump inhibition favoring association of PLB monomers into pentamers (34). Dark shading in membrane region of PLB indicates face of transmembrane helix interacting with calcium pump (103), and open area designates face of helix containing leucine/isoleucine zipper residues (194). K1 and K2 are hypothetical dissociation constants for PLB pentamer to monomer conversion and for PLB monomer binding to SERCA2a, respectively, as explicitly proposed in Ref. 103. [Adapted from Cornea et al. (34) and Kimura et al. (103).]
VI. PHOSPHOLAMBAN PHOSPHORYLATION AND FUNCTION IN INTACT SYSTEMS
Top
Previous
Next
References
-adrenergic stimulation (122, 134). Phosphorylation of PLB correlated temporally, over a time course of seconds, with the ability of the -agonist isoproterenol to accelerate the rate of relaxation of the heart (134) and occurred as a consequence of activation of cardiac 1-adrenergic receptors selectively (2, 248). When Ca2+-ATPase activity was analyzed in sarcoplasmic reticulum vesicles isolated from hearts subjected to -adrenergic stimulation, in which care was taken to prevent dephosphorylation of PLB during the preparation of membranes, it was observed that both Ca2+-ATPase (134) and calcium uptake (119) activities were increased as a result of PLB phosphorylation. Furthermore, the stimulation of calcium pump activity occurred most prominently at low ionized calcium concentration (55, 119, 134), showing that for PLB phosphorylated in vivo, like the protein phosphorylated in vitro, the main effect is on the calcium sensitivity of the ATPase, not on the Vmax . In other experiments, it was demonstrated that dephosphorylation of PLB, rather than of other cardiac protein substrates such as troponin I, C-protein, or phospholemman (56, 155, 219, 252), most closely paralleled termination of the mechanical effects of -adrenergic stimulation. Furthermore, cholinergic stimulation, which reverses the functional effects of -adrenergic stimulation, attenuated phosphorylation of PLB and Ca2+-ATPase activity at the same time that it increased the half time of relaxation (136). Thus, during -adrenergic stimulation of the heart, phosphorylation of PLB occurs rapidly, is regulated dynamically, and causes an increased rate of calcium transport into the sarcoplasmic reticulum. The resultant increase in rate of lowering of the cytoplasmic calcium concentration can account for the increased rate of myocardial relaxation produced by 1-agonists (215).-adrenergic stimulation were localized by monoclonal antibody affinity purification of the 32P-labeled protein from perfused guinea pig hearts followed by phosphoamino acid analysis and direct protein sequencing (242). It was observed that only serine-16 and threonine-17 were phosphorylated, indicating that in intact myocardium, -adrenergic stimulation results in PLB phosphorylation by both cAMP-dependent protein kinase (at serine-16) and calcium/calmodulin-dependent protein kinase (at threonine-17). During -adrenergic stimulation with isoproterenol, phosphorylation at serine-16 precedes that at threonine-17, but at steady state, both sites are phosphorylated in approximately equimolar amounts (242). Talosi et al. (219) subsequently showed that during termination of -adrenergic effects, dephosphorylation at serine-16 also precedes that at threonine-17, and proposed that the phosphorylation state of serine-16 correlates most closely with the mechanical effects. Immunoblotting of microsomes from hearts subjected to -adrenergic stimulation revealed 10 discrete mobility steps induced in the pentameric form of the protein (Fig. 4), confirming the additive phosphorylation of both sites on each monomer composing the pentamer during the time course of -agonist stimulation (242) and refuting an earlier proposal that there is no dephospho form of PLB in vivo in the basal unstimulated state (127). Phosphorylation of PLB by cAMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase was also observed by use of the back-phosphorylation technique in hearts from live animals administered isoproterenol (96). Thus dual phosphorylation of PLB occurs in vivo, as well as in vitro, with PLB regulating relaxant properties of the heart in a graded fashion by its incremental phosphorylation. -adrenergic agonists), but which do not increase cAMP, have no effect on PLB phosphorylation in intact hearts (133, 135, 166, 232, 233, 243). This paradox was recently addressed by Mundina-Weilenmann et al. (164), who took advantage of antibodies that distinguish between serine-16-phosphorylated PLB and threonine-17-phosphorylated PLB (38) to reassess mechanisms regulating PLB phosphorylation at these two sites in perfused hearts. Notably, when hearts were perfused at elevated extracellular calcium concentration in the presence of the phosphatase inhibitor okadaic acid, phosphorylation of threonine-17 of PLB readily occurred, and without any requirement for phosphorylation at serine-16. A significant decrease in the half-relaxation time coincided with this unique phosphorylation of threonine-17 (164). Thus phosphorylation of PLB at threonine-17 alone is sufficient to increase the cardiac relaxation rate, as originally predicted from results of calcium uptake assays utilizing sarcoplasmic reticulum vesicles (116, 174, 209). Under physiological conditions, inhibition of the major phosphatase that dephosphorylates PLB, the type 1 phosphatase (PP1) associated with cardiac sarcoplasmic reticulum (147), is apparently required to realize significant phosphorylation of PLB at threonine-17. Inhibition of PP1 activity associated with sarcoplasmic reticulum by cAMP-elevating agents occurs as a consequence of release of the catalytic subunit of the phosphatase from the membrane after phosphorylation of the regulatory subunit by cAMP-dependent protein kinase (1, 69), and also as a result of phosphorylation of phosphatase inhibitor 1 by cAMP-dependent protein kinase, which in the phosphorylated state is a potent inhibitor of PP1 catalytic activity (170). Supporting this mechanism, dephosphorylation of PLB in cardiac myoctyes is greatly stimulated by inactivation of cAMP-dependent protein kinase (252). For realization of the maximal contractile effect of PLB phosphorylation in intact myocardium, it thus appears that phosphorylation of both serine-16 and threonine-17 is required and that this requirement is only fulfilled by cAMP-dependent mechanisms involving an interplay between protein kinases and phosphatases (164).-adrenergic stimulation, it was always impossible to be absolutely certain that phosphorylation of PLB, by and of itself, was sufficient to alter myocardial contractile properties (97). In more recent work, the prime importance of PLB phosphorylation has been unambiguously demonstrated by two different approaches. In the first, ventricular myocytes were dialyzed with a monoclonal antibody to PLB that stimulates calcium uptake into sarcoplasmic reticulum at low ionized calcium concentration, and intracellular calcium transients were measured with the calcium-sensitive dye fura 2 (190). Dialysis of myocytes with the antibody significantly increased the amplitude and decreased the duration of the calcium transient, and effects of -agonist stimulation by isoproterenol on the calcium transient were virtually eliminated by the antibody (190). Thus removal of the inhibitory effect of PLB on the calcium pump of sarcoplasmic reticulum was proposed to be sufficient to elicit most of the effects of -adrenergic stimulation on the intracellular calcium transient in intact cardiac myocytes (190). Consistent with this conclusion, it was recently shown that overexpression of PLB in cultured cardiac myocytes by infection of cells with PLB-encoding adenovirus decreased the amplitude and increased the duration of the calcium transient (60b). -agonist stimulation of these transgenic hearts by isoproterenol was sharply attenuated, due to the fact that the basal state of contractility in the transgenic hearts was already close to the maximal level. Similar changes were shown in live PLB knockout mice by use of echocardiography (66). The results obtained from transgenic mouse hearts completely lacking the PLB protein (66, 144) are consistent with results from normal cardiomyoctyes dialyzed with the highly specific anti-PLB monoclonal antibody (190), demonstrating that PLB is a key suppressor of basal myocardial contractility and that phosphorylation of PLB can account for most of the contractile effects of 1-adrenergic stimulation on the heart, including both positive inotropic effects and enhanced relaxation (95, 114). The positive inotropic effect associated with -adrenergic stimulation of the heart arises from increased calcium loading by the sarcoplasmic reticulum, which makes more calcium available for calcium release. The augmented calcium release promotes more rapid calcium binding to troponin, stimulating tension development. The increased rate of muscle relaxation is a direct consequence of the accelerated rate of calcium removal from the cytoplasm, allowing calcium to be rapidly unbound from troponin (114, 210). Consistent with this idea, targeted overexpression of PLB to mouse ventricle (95a) or mouse atrium (168) in transgenic animals prolongs contraction time and depresses contractility in both tissues, whereas -adrenergic effects are amplified. Although -adrenergic-mediated contractile effects are strongly attenuated in PLB knockout mice, some contractile response to catecholamines does persist both in live animals (66) and in isolated myocytes (245a), suggesting that phosphorylation of proteins other than PLB (troponin I, ryanodine receptor, phospholemman, and dihydropyridine-sensitive calcium channel) may also play a role in regulating contraction-relaxation dynamics of heart cells (245a).1-adrenergic effects by modulating the calcium sensitivity, but not the Vmax , of the calcium pump.
VII. PHOSPHOLAMBAN EXPRESSION IN HUMAN HEART FAILURE
Top
Previous
Next
References
VIII. CONCLUDING REMARKS
Top
Previous
Next
References
-adrenergic mechanisms regulating contractility in mammalian heart. As such, understanding the structure-function relationships of PLB and the protein-protein interactions with which it participates will be necessary to exploit its activities for therapeutically useful purposes.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Charles Fisch, founding director of the Krannert Institute of Cardiology, who supported much of our early work on phospholamban. L. R. Jones is the Charles Fisch Professor of Cardiology.
| |
FOOTNOTES |
|---|
Studies from the authors' laboratory were funded by National Heart, Lung, and Blood Institute Grants HL-06308 and HL-49428.
| |
REFERENCES |
|---|
|
TopPrevious |
|---|
1.
AHMAD, Z.,
F. J. GREEN,
H. SUBUHI,
AND A. M. WATANABE.
Autonomic regulation of type 1 protein phosphatase in cardiac muscle.
J. Biol. Chem.
264: 3859-3863, 1989
2.
ALTSCHULD, R. A.,
R. C. STARLING,
R. L. HAMLIN,
G. E. BILLMAN,
J. HENSLEY,
L. CASTILLO,
R. H. FERTEL,
C. M. HOHL,
P.-M. L. ROBITAILLE,
L. R. JONES,
R.-P. XIAO,
AND E. G. LAKATTA.
Response of failing canine and human heart cells to 2-adrenergic stimulation.
Circulation
92: 1612-1618, 1995
3. AMBUDKAR, I. S., AND A. E. SHAMOO. Role of phospholamban in regulating cardiac sarcoplasmic reticulum calcium pump. Membr. Biochem. 5: 119-130, 1984[Medline].
4. ANDERSON, J. P.. Monomer oligomer equilibrium of sarcoplasmic reticulum Ca-ATPase and the role of subunit interaction in the Ca2+ pump mechanism. Biochim. Biophys. Acta 988: 47-72, 1989[Medline].
5.
ANTIPENKO, A. Y.,
A. I. SPIELMAN,
AND M. A. KIRCHBERGER.
Comparison of the effects of phospholamban and jasmone on the calcium pump of cardiac sarcoplasmic reticulum.
J. Biol. Chem.
272: 2852-2860, 1997
5a. ANTIPENKO, A. Y., A. I. SPIELMAN, M. SASSAROLI, AND M. A. KIRCHBERGER. Comparison of the kinetic effects of phospholamban phosphorylation and anti-phospholamban monoclonal antibody on the calcium pump in purified cardiac sarcoplasmic reticulum membranes. Biochemistry 36: 12903-12910, 1997[Medline].
6.
ARAI, M.,
N. R. ALPERT,
D. H. MACLENNAN,
P. BARTON,
AND M. PERIASAMY.
Alterations in sarcoplasmic gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium.
Circ. Res.
72: 463-469, 1993
7. ARKIN, I. T., P. D. ADAMS, A. T. BRÜNGER, S. O. SMITH, AND D. M. ENGELMAN. Structural perspectives of phospholamban, a helical transmembrane pentamer. Annu. Rev. Biophys. Biomol. Struct. 26: 157-179, 1997[Medline].
8. ARKIN, I. T., P. D. ADAMS, K. R. MACKENZIE, M. A. LEMMON, A. T. BRÜNGER, AND D. M. ENGELMAN. Structural organization of the pentameric transmembrane alpha-helices of phospholamban, a cardiac ion channel. EMBO J. 13: 4757-4764, 1994[Medline].
9. ARKIN, I. T., K. R. MACKENZIE, L. FISHER, S. AIMOTO, D. M. ENGELMAN, AND S. O. SMITH. Mapping the lipid-exposed surfaces of membrane proteins. Nature Struct. Biol. 3: 240-243, 1996[Medline].
10. ARKIN, I. T., M. ROTHMAN, C. F. C. LUDLAM, S. AIMOTO, D. M. ENGELMAN, K. J. ROTHSCHILD, AND S. O. SMITH. Structural model of the phospholamban ion channel complex in phospholipid membranes. J. Mol. Biol. 248: 824-834, 1995[Medline].
11. AUTRY, J. M., S. E. CALA, B. T. SCOTT, AND L. R. JONES. High level co-expression of the canine cardiac calcium pump and phospholamban in Sf21 insect cells. Ann. NY Acad. Sci. 853: 92-102, 1998[Medline].
12.
AUTRY, J. M.,
AND L. R. JONES.
Functional co-expression of the canine cardiac Ca2+-pump and phospholamban in Sf21 cells reveals new insights on ATPase regulation.
J. Biol. Chem.
272: 15872-15880, 1997
13.
BEEKMAN, R. E.,
C. VANHARDEVELD,
AND W. S. SIMONIDES.
On the mechanism of the reduction by thyroid hormone of -adrenergic relaxation rate stimulation in rat heart.
Biochem. J.
259: 229-236, 1989[Medline].
14.
BIDLACK, J. M.,
I. S. AMBUDKAR,
AND A. E. SHAMOO.
Purification of phospholamban, a 22,000-dalton protein from cardiac sarcoplasmic reticulum that is specifically phosphorylated by cyclic AMP-dependent protein kinase.
J. Biol. Chem.
257: 4501-4506, 1982
15. BIDLACK, J. M., AND A. E. SHAMOO. Adenosine 3',5'-monophosphate-dependent phosphorylation of a 6,000 and a 22,000-dalton protein from cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 632: 310-325, 1980[Medline].
16.
BILEZIKJIAN, L. M.,
E. G. KRANIAS,
J. D. POTTER,
AND A. SCHWARTZ.
Studies on phosphorylation of canine cardiac sarcoplasmic reticulum by calmodulin-dependent protein kinase.
Circ. Res.
49: 1356-1362, 1981
17. BÖHM, M., B. REIGER, R. H. G. SCHWINGER, AND E. ERDMANN. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc. Res. 28: 1713-1719, 1994[Medline].
18. BOYOT, P., B. LUU, L. R. JONES, AND E. TRIFILIEFF. Purification of phospholamban from bovine cardiac muscle with organic solvents. Arch. Biochem. Biophys. 269: 639-645, 1989[Medline].
19. BRIGGS, N. F., K. F. LEE, J. J. FEHER, A. S. WECHSLER, K. OHLENDIECK, AND K. P. CAMPBELL. Ca-ATPase isozyme expression in sarcoplasmic reticulum is altered by chronic stimulation of skeletal muscle. FEBS Lett. 259: 269-272, 1990[Medline].
20.
BRIGGS, F. N.,
K. F. LEE,
A. W. WECHSLER,
AND L. R. JONES.
Phospholamban expressed in slow-twitch and chronically stimulated fast-twitch muscles minimally affects calcium affinity of sarcoplasmic reticulum Ca2+-ATPase.
J. Biol. Chem.
267: 26056-26061, 1992
21.
BURK, S. E.,
J. LYTTON,
D. H. MACLENNAN,
AND G. E. SHULL.
cDNA cloning, functional expression, and mRNA tissue distribution of a third organellar Ca2+ pump.
J. Biol. Chem.
264: 18561-18568, 1989
22.
CANTILINA, T.,
Y. SAGARA,
G. INESI,
AND L. R. JONES.
Comparative studies of cardiac and skeletal sarcoplasmic reticulum ATPases: effect of a phospholamban antibody on enzyme activation by Ca2+.
J. Biol. Chem.
268: 17018-17025, 1993
23. CAPONY, J.-P., M. L. RINALDI, F. GUILLEUX, AND J. G. DEMAILLE. Isolation of cardiac membrane proteolipids by high pressure liquid chromatography: a comparison of reticular and sarcolemmal proteolipids, phospholamban and calciductin. Biochim. Biophys. Acta 728: 83-91, 1983[Medline].
24. CHEN, W., M. LAH, P. J. ROBINSON, AND B. E. KEMP. Phosphorylation of phospholamban in aortic smooth muscle cells and heart by calcium/calmodulin-dependent protein kinase II. Cell. Signal. 6: 617-630, 1994[Medline].
25. CHIESI, M., J. GASSER, AND E. CARAFOLI. Phospholamban of cardiac sarcoplasmic reticulum consists of two functionally distinct proteolipids. FEBS Lett. 160: 61-66, 1983[Medline].
26. CHIESI, M., AND R. SCHWALLER. Involvement of electrostatic phenomena in phospholamban-induced stimulation of Ca uptake into cardiac sarcoplasmic reticulum. FEBS Lett. 244: 241-244, 1989[Medline].
27. CHIESI, M., AND R. SCHWALLER. Reversal of phospholamban-induced inhibition of cardiac sarcoplasmic reticulum Ca2+-ATPase by tannin. Biochem. Biophys. Res. Commun. 202: 1668-1673, 1994[Medline].
28. CHIESI, M., T. VORHERR, R. FALCHETTO, C. WAELCHLI, AND E. CARAFOLI. Phospholamban is related to the autoinhibitory domain of the plasma membrane Ca2+-pumping ATPase. Biochemistry 30: 7978-7983, 1991[Medline].
29. CHU, G., G. W. DORN II, W. LUO, J. M. HARRER, V. J. KADAMBI, R. A. WALSH, AND E. G. KRANIAS. Monomeric phospholamban overexpression in transgenic mouse hearts. Circ. Res. 81: 485-492, 1997.
29a.
CHU, G.,
W. LUO,
J. P. SLACK,
C. TILGMANN,
W. E. SWEET,
M. SPINDLER,
K. W. SAUPE,
G. P. BOIVIN,
C. S. MORAVEC,
M. A. MATLIB,
I. L. GRUPP,
J. S. INGWALL,
AND E. G. KRANIAS.
Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts.
Circ. Res.
78: 1064-1076, 1996
30. COLLINS, J. G., E. G. KRANIAS, A. S. REEVES, L. M. BILEZIKJIAN, AND A. SCHWARTZ. Isolation of phospholamban and a second proteolipid component from canine cardiac sarcoplasmic reticulum. Biochem. Biophys. Res. Commun. 99: 796-803, 1981[Medline].
31. COLYER, J. Control of the calcium pump of cardiac sarcoplasmic reticulum. A specific role for the pentameric structure of phospholamban? Cardiovasc. Res. 27: 1766-1771, 1993.
32.
COLYER, J.,
AND J. H. WANG.
Dependence of cardiac sarcoplasmic reticulum calcium pump activity on the phosphorylation status of phospholamban.
J. Biol. Chem.
266: 17486-17493, 1991
33. COOK, E. A., J. P. HUGGINS, G. SATHE, P. J. ENGLAND, AND J. R. PIGGOTT. The expression of canine cardiac phospholamban in heterologous systems. Biochem. J. 264: 533-538, 1989[Medline].
34. CORNEA, R. L., L. R. JONES, J. M. AUTRY, AND D. D. THOMAS. Mutation and phosphorylation change the oligomeric state of phospholamban in lipid bilayers. Biochemistry 36: 2960-2967, 1997[Medline].
35. CORNWELL, T. L., K. B. PRYZWANSKI, T. A. WYATT, AND T. M. LINCOLN. Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells. Mol. Pharmacol. 40: 923-931, 1991[Abstract].
36. DAVIS, B. A., I. EDES, R. C. GUPTA, E. F. YOUNG, AND H. W. KIM. N. A. E. STEENAART, G. SZYMANSKA, AND E. G. KRANIAS. The role of phospholamban in the regulation of calcium transport by cardiac sarcoplasmic reticulum. Mol. Cell. Biochem. 99: 83-88, 1990[Medline].
37.
DECROUY, A.,
M. JUTEAU,
AND E. ROUSSEAU.
Examination of the role of phosphorylation and phospholamban in the regulation of the cardiac sarcoplasmic reticulum Cl channel.
J. Membr. Biol.
146: 315-326, 1995[Medline].
37a. DIECKMANN, G. R., AND W. F. DEGRADO. Modeling transmembrane and helical oligomers. Curr. Opin. Struct. Biol. 7: 486-494, 1997[Medline].
38.
DRAGO, G. A.,
AND J. COLYER.
Discrimination between two sites of phosphorylation on adjacent amino acids by phosphorylation site-specific antibodies.
J. Biol. Chem.
269: 25073-25077, 1994
39. EDES, I., AND E. G. KRANIAS. Regulation of cardiac sarcoplasmic reticulum function by phospholamban. Membr. Biochem. 7: 175-192, 1987[Medline].
40.
EDES, I.,
AND E. G. KRANIAS.
Phospholamban and troponin I are substrates for protein kinase C in vitro but not in intact beating guinea pig hearts.
Circ. Res.
67: 394-400, 1990
41.
EGGERMONT, J. A.,
M. VROLIX,
L. RAEYMAKERS,
F. WUYTACK,
AND R. CASTEELS.
Ca2+-transport ATPases of vascular smooth muscle.
Circ. Res.
62: 266-278, 1988
42. EGGERMONT, J. A., F. WUYTACK, J. VERBIST, AND R. CASTEELS. Expression of endoplasmic-reticulum Ca2+-pump isoforms and of phospholamban in pig smooth-muscle tissues. Biochem. J. 271: 649-653, 1990[Medline].
43.
FELDMAN, A.,
E. R. PHILLIP,
C. M. SILAN,
J. A. MERCER,
W. MINOBE,
AND M. R. BRISTOW.
Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction.
Circulation
83: 1866-1872, 1991
44.
FERGUSON, D. G.,
E. F. YOUNG,
L. RAEYMAEKERS,
AND E. G. KRANIAS.
Localization of phospholamban in smooth muscle using immunogold electron microscopy.
J. Cell Biol.
107: 555-562, 1988
45. FLEISCHER, S.. Phospholamban, phosphorylation, and phosphorescence. Biophys. J. 67: 3-4, 1994[Medline].
46. FLESCH, M., R. H. G. SCHWINGER, P. SCHNABEL, F. SCHIFFER, I. VAN GELDER, U. BAVENDIEK, M. SUDKAMP, F. REGNIER-KUHN, AND M. BOHM. Sarcoplasmic reticulum Ca2+-ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J. Mol. Med. 74: 321-332, 1996[Medline].
47. FLOCKERZI, V., R. MEWES, P. RUTH, AND F. HOFMAN. Phosphorylation of purified bovine cardiac sarcolemma and potassium-stimulated calcium uptake. Eur. J. Biochem. 135: 131-142, 1983[Medline].
48. FOWLER, C., J. P. HUGGINS, C. HALL, C. J. RESTALL, AND D. CHAPMAN. The effects of calcium, temperature and phospholamban phosphorylation on the dynamics of the calcium-stimulated ATPase of canine cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 980: 348-356, 1989[Medline].
49. FUJII, J., M. KADOMA, M. TADA, H. TADA, AND F. SAKIYAMA. Characterization of structural unit of phospholamban by amino acid sequencing and electrophoretic analysis. Biochem. Biophys. Res. Commun. 138: 1044-1050, 1986[Medline].
50. FUJII, J., J. LYTTON, M. TADA, AND D. H. MACLENNAN. Rabbit cardiac and slow-twitch muscle express the same phospholamban gene. FEBS Lett. 227: 51-55, 1988[Medline].
51.
FUJII, J.,
K. MARUYAMA,
M. TADA,
AND D. H. MACLENNAN.
Expression and site-specific mutagenesis of phospholamban: studies of residues involved in phosphorylation and pentamer formation.
J. Biol. Chem.
264: 12950-12955, 1989
52. FUJII, J., K. MARUYAMA, M. TADA, AND D. H. MACLENNAN. Co-expression of slow-twitch/cardiac muscle Ca2+-ATPase (SERCA2) and phospholamban. FEBS Lett. 273: 232-234, 1990[Medline].
53. FUJII, J., A. UENO, K. KITANO, S. TANAKA, M. KADOMA, AND M. TADA. Complete complemetary DNA-derived amino acid sequence of canine cardiac phospholamban. J. Clin. Invest. 79: 301-304, 1987.
54.
FUJII, J.,
A. ZARAIN-HERZBERG,
H. F. WILLARD,
M. TADA,
AND D. H. MACLENNAN.
Structure of the rabbit phospholamban gene, cloning of the human cDNA, and assignment of the gene to human chromosome 6.
J. Biol. Chem.
266: 11669-11675, 1991
55.
GANIM, J. R.,
W. LUO,
S. PONNIAH,
I. GRUPP,
H. W. KIM,
D. G. FERGUSON,
V. KADAMBI,
J. C. NEUMANN,
T. DOETSCHMAN,
AND E. G. KRANIAS.
Mouse phospholamban gene expression during development in vivo and in vitro.
Circ. Res.
71: 1021-1030, 1992
56. GARVEY, J. L., E. G. KRANIAS, AND R. J. SOLARO. Phosphorylation of C protein, troponin I, and phospholamban in isolated rabbit hearts. Biochem. J. 249: 709-714, 1988[Medline].
57. GASSER, J. T., M. P. CHIESI, AND E. CARAFOLI. Concerted phosphorylation of the 26-kilodalton phospholamban oligomer and of the low molecular weight phospholamban subunits. Biochemistry 25: 7615-7623, 1986[Medline].
58.
GREENGARD, P..
Phosphorylated proteins as physiological effectors.
Science
199: 146-152, 1978
59. GRUPP, I. L., E. G. KRANIAS, J. M. HARRER, E. KISS, J. SLACK, K. L. KOSS, I. EDES, W. LUO, AND G. GRUPP. The contribution of phospholamban, a sarcoplasmic reticulum phosphoprotein, to myocardial contractility in health and disease. Heart Failure 11: 48-61, 1995.
60. GUPTA, R. C., AND E. G. KRANIAS. Purification and characterization of a calcium-calmodulin-dependent phospholamban kinase from canine myocardium. Biochemistry 28: 5909-5916, 1989[Medline].
60a. HAGHIGHI, K., V. J. KADAMBI, K. L. KOSS, W. LUO, J. M. HARRER, S. PONNIAH, Z. ZHOU, AND E. G. KRANIAS. In vitro and in vivo promoter analyses of the mouse phospholamban gene. Gene 203: 199-207, 1997[Medline].
60b.
HAJJAR, R. J.,
U. SCHMIDT,
J. X. KANG,
T. MATSUI,
AND A. ROSENZWEIG.
Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes: rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca2+-ATPase.
Circ. Res.
81: 145-153, 1997
61. HARRER, J. M., AND E. G. KRANIAS. Characterization of the molecular form of cardiac phospholamban. Mol. Cell. Biochem. 140: 185-193, 1994[Medline].
62. HARRER, J. M., S. PONNIAH, D. G. FERGUSON, AND E. G. KRANIAS. Expression of phospholamban in C2C12 cells and regulation of endogenous SERCA1 activity. Mol. Cell. Biochem. 146: 13-21, 1995[Medline].
63. HARTMANN, M., AND J. SCHRADER. Protein kinase C phosphorylates a 15 kDa protein but not phospholamban in intact rat cardiac myocytes. Eur. J. Pharmacol. 226: 225-231, 1992[Medline].
64.
HASENFUSS, G.,
H. REINECKE,
R. STUDER,
M. MEYER,
B. PIESKE,
J. HOLTZ,
C. HOLUBARSCH,
H. POSIVAL,
H. JUST,
AND H. DREXLER.
Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium.
Circ. Res.
75: 434-442, 1994
64a. HERZYK, P., AND R. E. HUBBARD. Using experimental information to produce a model of the transmembrane domain of the ion channel phospholamban. Biophys. J. 74: 1203-1214, 1998[Medline].
65.
HICKS, M.,
M. SHIGEKAWA,
AND A. M. KATZ.
Mechanism by which cyclic adenosine 3':5'-monophosphate-dependent protein kinase stimulates calcium transport in cardiac sarcoplasmic reticulum.
Circ. Res.
44: 384-391, 1979
66.
HOIT, B. D.,
S. F. KHOURY,
E. G. KRANIAS,
N. BALL,
AND R. A. WALSH.
In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency.
Circ. Res.
77: 632-637, 1995
67. HOLTZHAUER, M., H. SYDOW, AND T. S. LEVCHENKO. The putative role of phospholamban in the regulation of the heart muscle. Biomed. Biochim. Acta 45: S233-S236, 1986[Medline].
68.
HU, P.,
C. YIN,
K.-M. ZHANG,
L. D. WRIGHT,
T. E. NIXON,
A. S. WECHSLER,
J. A. SPRATT,
AND F. N. BRIGGS.
Transcriptional regulation of phospholamban gene and translational regulation of SERCA2 gene produce coordinate expression of these two sarcoplasmic reticulum proteins during skeletal muscle phenotype switching.
J. Biol. Chem.
270: 11619-11622, 1995
68a. HU, P., K.-M. ZHANG, J. A. SPRATT, A. S. WECHSLER, AND F. N. BRIGGS. Transcription rates of SERCA and phospholamban genes change in response to chronic stimulation of skeletal muscle. Biochim. Biophys. Acta 1395: 121-125, 1998[Medline].
69. HUBBARD, M. J., P. DENT, C. SMYTHE, AND P. COHEN. Targeting of protein phosphatase 1 to the sarcoplasmic reticulum of rabbit skeletal muscle by a protein that is very similar or identical to the G subunit that directs the enzyme to glycogen. Eur. J. Biochem. 189: 243-249, 1990[Medline].
70. HUBBARD, J. A., L. K. MACLACHLAN, E. MEENAN, C. J. SALTER, D. G. REID, P. LAHOURATATE, J. HUMPHRIES, N. STEVENS, D. BELL, W. A. NEVILLE, K. J. MURRAY, AND J. G. DARKER. Conformation of the cytoplasmic domain of phospholamban by NMR and CD. Mol. Membr. Biol. 11: 263-269, 1994[Medline].
71. HUGGINS, J. P., E. A. COOK, J. R. PIGGOTT, T. J. MATTINSLEY, AND P. J. ENGLAND. Phospholamban is a good substrate for cyclic GMP-dependent protein kinase in vitro, but not in intact cardiac or smooth muscle. Biochem. J. 260: 829-835, 1989[Medline].
72. HUGGINS, J. P., AND P. J. ENGLAND. Sarcolemmal phospholamban is phosphorylated in isolated rat hearts perfused with isoprenaline. FEBS Lett. 163: 297-302, 1983[Medline].
73. HUGGINS, J. P., AND P. J. ENGLAND. Evidence for a phosphorylation-induced conformational change in phospholamban from the effects of three proteases. FEBS Lett. 217: 32-36, 1987[Medline].
74. HUGHES, G., J. M. EAST, AND A. G. LEE. The hydrophilic domain of phospholamban inhibits the Ca2+ transport step of the Ca2+-ATPase. Biochem. J. 303: 511-516, 1994.
75. HUGHES, G., A. P. STARLING, R. P. SHARMA, J. M. EAST, AND A. LEE. An investigation of the mechanism of inhibition of the Ca2+-ATPase by phospholamban. Biochem. J. 318: 973-979, 1996.
76. HWANG, K. S., AND B. NADAL-GINARD. Cloning phospholamban cDNA from rat aortic smooth muscle. Adv. Exp. Med. Biol. 304: 387-395, 1991[Medline].
77.
IMAGAWA, T.,
T. WATANABE,
AND T. NAKAMURA.
Subunit structure and multiple phosphorylation sites of phospholamban.
J. Biochem.
99: 41-53, 1986
78.
INUI, M.,
B. H. CHAMBERLAIN,
A. SAITO,
AND S. FLEISCHER.
The nature of the modulation of Ca2+ transport as studied by reconstitution of cardiac sarcoplasmic reticulum.
J. Biol. Chem.
261: 1794-1800, 1986
79.
INUI, M.,
M. KADOMA,
AND M. TADA.
Purification and characterization of phospholamban from canine cardiac sarcoplasmic reticulum.
J. Biol. Chem.
260: 3708-3715, 1985
80.
IWASA, Y.,
AND M. M. HOSEY.
Phosphorylation of cardiac sarcolemma proteins by the calcium-activated phospholipid-dependent protein kinase.
J. Biol. Chem.
259: 534-540, 1984
81. JACKSON, W. A., AND J. COLYER. Release of Ca2+-Mg2+ ATPase inhibition by phospholamban phosphorylation (Abstract). Biochem. Soc. Trans. 62S: 23, 1995.
82. JACKSON, W. A., AND J. COLYER. Translation of Ser16 and Thr17 phosphorylation of phospholamban into Ca2+-pump stimulation. Biochem. J. 316: 201-207, 1996.
83. JAKAB, G., AND E. G. KRANIAS. Phosphorylation and dephosphorylation of purified phospholamban and associated phosphatidylinositides. Biochemistry 27: 3799-3806, 1988[Medline].
84. JAMES, P., M. INUI, M. TADA, M. CHIESI, AND E. CARAFOLI. Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum. Nature 342: 90-92, 1989[Medline].
85. JOHNS, D. C., AND A. M. FELDMAN. Identification of a highly conserved region at the 5' flank of the phospholamban gene. Biochem. Biophys. Res. Commun. 188: 927-933, 1992[Medline].
86.
JONES, L. R..
Sarcolemmal enzymes mediating -adrenergic effects on the heart.
Curr. Top. Membr. Transp.
25: 11-41, 1985.
87.
JONES, L. R.,
H. R. BESCH,
J. W. FLEMING,
M. M. MCCONNAUGHEY,
AND A. M. WATANABE.
Separation of vesicles of cardiac sarcolemma from vesicles of cardiac sarcoplasmic reticulum: comparative biochemical analysis of component activities.
J. Biol. Chem.
254: 530-539, 1979
88.
JONES, L. R.,
AND L. J. FIELD.
Residues 2-25 of phospholamban are insufficient to inhibit Ca2+ transport ATPase of cardiac sarcoplasmic reticulum.
J. Biol. Chem.
268: 11486-11488, 1993
89. JONES, L. R., S. W. MADDOCK, AND D. R. HATHAWAY. Membrane localization of myocardial type II cAMP-dependent protein kinase activity. Biochim. Biophys. Acta 641: 242-253, 1981[Medline].
90.
JONES, L. R.,
H. K. B. SIMMERMAN,
W. W. WILSON,
F. R. N. GURD,
AND A. D. WEGENER.
Purification and characterization of phospholamban from canine cardiac sarcoplasmic reticulum.
J. Biol. Chem.
260: 7721-7730, 1985
91. JONES, L. R., A. D. WEGENER, AND H. K. B. SIMMERMAN. Purification of phospholamban from canine cardiac sarcoplasmic reticulum vesicles by use of sulfhydryl group affinity chromatography. Methods Enzymol. 157: 360-369, 1988[Medline].
92.
JORGENSEN, A. O.,
AND L. R. JONES.
Localization of phospholamban in slow but not fast canine skeletal muscle fibers: an immunocytochemical and biochemical study.
J. Biol. Chem.
261: 3775-3781, 1986
93.
JORGENSEN, A. O.,
AND L. R. JONES.
Immunoelectron microscopical localization of phospholamban in adult canine ventricular muscle.
J. Cell Biol.
104: 1343-1352, 1987
94.
JORGENSEN, A. O.,
A.-Y. SHEN,
W. ARNOLD,
P. S. MCPHERSON,
AND K. P. CAMPBELL.
The Ca2+-release channel/ryanodine receptor is localized in junctional and corbular sarcoplasmic reticulum in cardiac muscle.
J. Cell Biol.
120: 969-980, 1993
95. KADAMBI, V. J., AND E. G. KRANIAS. Phospholamban: a protein coming of age. Biochem. Biophys. Res. Commun. 239: 1-5, 1997[Medline].
95a. KADAMBI, V. J., S. PONNIAH, J. M. HARRER, B. D. HOIT, G. W. DORN II, R. A. WALSH, AND E. G. KRANIAS. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97: 533-539, 1996.
96. KARCZEWSKI, P., S. BARTEL, H. HAASE, AND E.-G. KRAUSE. Isoproterenol induces both cAMP- and calcium-dependent phosphorylation of phospholamban in canine heart in vivo. Biomed. Biochim. Acta 46: S433-S439, 1987[Medline].
97. KARCZEWSKI, P., S. BARTEL, AND E.-G. KRAUSE. Differential sensitivity to isoprenaline of troponin I and phospholamban phosphorylation in isolated rat hearts. Biochem. J. 266: 115-122, 1990[Medline].
98. KARCZEWSKI, P., M. KELM, M. HARTMANN, AND J. SCHRADER. Role of phospholamban in NO/EDRF-induced relaxation in rat aorta. Life Sci. 51: 1205-1210, 1992[Medline].
99. KATZ, A. M., R. A. COLVIN, AND T. ASHAVAID. Phospholamban and calciductin. J. Mol. Cell. Cardiol. 15: 795-797, 1983[Medline].
100.
KIM, H. W.,
N. A. E. STEENAART,
D. G. FERGUSON,
AND E. G. KRANIAS.
Functional reconstitution of the cardiac sarcoplasmic reticulum Ca2+-ATPase with phospholamban in phospholipid vesicles.
J. Biol. Chem.
265: 1702-1709, 1990
101. KIMURA, Y., M. INUI, M. KADOMA, Y. KIJIMA, T. SASAKI, AND M. TADA. Effects of monoclonal antibody against phospholamban on calcium pump ATPase of cardiac sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 23: 1223-1230, 1991[Medline].
102.
KIMURA, Y.,
K. KURZYDLOWSKI,
M. TADA,
AND D. H. MACLENNAN.
Phospholamban regulates the Ca2+-ATPase through intramembrane interactions.
J. Biol. Chem.
271: 21726-21731, 1996
103.
KIMURA, Y.,
K. KURZYDLOWSKI,
M. TADA,
AND D. H. MACLENNAN.
Phospholamban inhibitory function is activated by depolymerization.
J. Biol. Chem.
272: 15061-15064, 1997
104. KIMURA, Y., K. OTSU, K. NISHIDA, T. KUZUYA, AND M. TADA. Thyroid hormone enhances Ca2+ pumping activity of the cardiac sarcoplasmic reticulum by increasing Ca2+ ATPase and decreasing phospholamban expression. J. Mol. Cell. Cardiol. 26: 1145-1154, 1994[Medline].
105. KIRCHBERGER, M. A., AND T. ANTONETZ. Phospholamban: dissociation of the 22,000 molecular weight protein of cardiac sarcoplasmic reticulum into 11,000 and 5,500 molecular weight forms. Biochem. Biophys. Res. Commun. 105: 152-156, 1982[Medline].
106.
KIRCHBERGER, M. A.,
AND T. ANTONETZ.
Calmodulin-mediated regulation of calcium transport and (Ca2+ + Mg2+)-activated ATPase activity in isolated cardiac sarcoplasmic reticulum.
J. Biol. Chem.
257: 5685-5691, 1982
107. KIRCHBERGER, M. A., D. BORCHMAN, AND C. KASINATHAN. Proteolytic activation of the canine cardiac sarcoplasmic reticulum calcium pump. Biochemistry 25: 5484-5492, 1986[Medline].
108. KIRCHBERGER, M. A., AND A. RAFFO. Decrease in calcium transport associated with phosphoprotein phosphatase-catalyzed dephosphorylation of cardiac sarcoplasmic reticulum. J. Cyclic Nucleotide Res. 3: 45-53, 1997.
109.
KIRCHBERGER, M. A.,
AND M. TADA.
Effects of adenosine 3',5'-monophosphate dependent protein kinase on sarcoplasmic reticulum isolated from cardiac and slow and fast contracting skeletal muscles.
J. Biol. Chem.
251: 725-729, 1976
110.
KIRCHBERGER, M. A.,
M. TADA,
AND A. M. KATZ.
Adenosine 3':5'-monophosphate-dependent protein kinase catalyzed phosphorylation reaction and its relationship to calcium transport in cardiac sarcoplasmic reticulum.
J. Biol. Chem.
249: 6166-6173, 1974
111. KIRCHBERGER, M. A., M. TADA, AND A. M. KATZ. Phospholamban: a regulatory protein of the cardiac sarcoplasmic reticulum. Recent Adv. Stud. Cardiac Struct. Metab. 5: 103-115, 1975[Medline].
112.
KISS, E.,
N. A. BALL,
E. G. KRANIAS,
AND R. A. WALSH.
Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca2+-ATPase protein levels.
Circ. Res.
77: 759-764, 1995
113.
KISS, E.,
G. JAKAB,
E. G. KRANIAS,
AND I. EDES.
Thyroid hormone-induced alterations in phospholamban protein expression: regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation.
Circ. Res.
75: 245-251, 1994
113a.
KORECKY, B.,
R. ZAK,
K. SCHWARTZ,
AND V. ASCHENBRENNER.
Role of thyroid hormone in regulation of isomyosin composition, contractility, and size of heterotopically isotransplanted rat heart.
Circ. Res.
60: 824-830, 1987
114.
KOSS, K. L.,
AND E. G. KRANIAS.
Phospholamban: a prominent regulator of myocardial contractility.
Circ. Res.
79: 1059-1063, 1996
115.
KOVACS, R. J.,
M. T. NELSON,
H. K. B. SIMMERMAN,
AND L. R. JONES.
Phospholamban forms Ca2+-selective channels in lipid bilayers.
J. Biol. Chem.
263: 18364-18368, 1988
116. KRANIAS, E. G.. Regulation of Ca2+ transport by cyclic 3',5'-AMP-dependent and calcium-calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 844: 193-199, 1985[Medline].
117.
KRANIAS, E. G..
Regulation of calcium transport by protein phosphatase activity associated with cardiac sarcoplasmic reticulum.
J. Biol. Chem.
260: 11006-11010, 1985
118.
KRANIAS, E. G.,
AND J. DISALVO.
A phospholamban protein phosphatase activity associated with cardiac sarcoplasmic reticulum.
J. Biol. Chem.
261: 10029-10032, 1986
119. KRANIAS, E. G., J. L. GARVEY, R. D. SRIVASTAVA, AND R. J. SOLARO. Phosphorylation and functional modifications of sarcoplasmic reticulum and myofibrils in isolated rabbit hearts stimulated with isoprenaline. Biochem. J. 226: 113-121, 1985[Medline].
120. KRANIAS, E. G., F. MANDEL, T. WANG, AND A. SCHWARTZ. Mechanism of the stimulation of calcium ion dependent adenosine triphosphatase of cardiac sarcoplasmic reticulum by adenosine 3',5'-dependent protein kinase. Biochemistry 19: 5434-5439, 1980[Medline].
121. KRANIAS, E. G., J. NAKAMURA, AND A. SCHWARTZ. Phospholamban, the regulator of the cardiac sarcoplasmic reticulum calcium pump, does not copurify with the Ca2+-ATPase enzyme. Biochim. Biophys. Acta 749: 62-68, 1983[Medline].
122. KRANIAS, E. G., AND R. J. SOLARO. Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature 298: 182-184, 1982[Medline].
123.
KUO, J. F.,
AND P. GREENGARD.
Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adenosine 3',5'-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom.
Proc. Natl. Acad. Sci. USA
64: 1349-1355, 1969
123a.
LALLI, J.,
J. M. HARRER,
E. G. KRANIAS,
AND R. J. PAUL.
Targeted ablation of the phospholamban gene is associated with a marked decrease in sensitivity in aortic smooth muscle.
Circ. Res.
80: 506-513, 1997
124. LAMERS, J. M. J., AND J. T. STINIS. Phosphorylation of low molecular weight proteins in purified preparations of rat heart sarcolemma and sarcoplasmic reticulum. Biochim. Biophys. Acta 624: 443-459, 1980[Medline].
125.
LARAIA, P. J.,
AND E. MORKIN.
Adenosine 3',5'-monophosphate-dependent membrane phosphorylation: a possible mechanism for the control of microsomal calcium transport in heart muscle.
Circ. Res.
35: 298-306, 1974
126. LEBERER, E., K.-T. HÄRTNER, C. J. BRANDL, J. FUJII, M. TADA, D. H. MACLENNAN, AND D. PETTE. Slow/cardiac sarcoplasmic reticulum Ca2+-ATPase and phospholamban mRNAs are expressed in chronically stimulated rabbit fast-twitch muscle. Eur. J. Biochem. 185: 51-54, 1989[Medline].
127.
LEPEUCH, C. J.,
J.-C. GUILLEUX,
AND J. G. DEMAILLE.
Phospholamban phosphorylation in the perfused rat heart is not solely dependent on -adrenergic stimulation.
FEBS Lett.
114: 165-168, 1980[Medline].
128. LEPEUCH, C. J., J. HAIECH, AND J. G. DEMAILLE. Concerted regulation of cardiac sarcoplasmic reticulum calcium transport by cyclic adenosine monophosphate-dependent and calcium-calmodulin-dependent phosphorylations. Biochemistry 18: 5150-5157, 1979[Medline].
129. LEPEUCH, C. J., D. A. M. LEPEUCH, AND J. G. DEMAILLE. Phospholamban, activator of the cardiac sarcoplasmic reticulum calcium pump: physicochemical properties and diagonal purification. Biochemistry 19: 3368-3373, 1980[Medline].
130. LEPEUCH, C. J., D. A. M. LEPEUCH, AND J. G. DEMAILLE. Covalent regulation of the cardiac sarcoplasmic reticulum calcium pump: purification and properties of phospholamban, a substrate of cAMP-dependent protein kinase and Ca2+-calmodulin-dependent protein phospholamban kinase. Methods Enzymol. 102: 261-278, 1983[Medline].
131. LI, C., J. H. WANG, AND J. COLYER. Immunological detection of phospholamban phosphorylation states facilitates the description of the mechanism of phosphorylation and dephosphorylation. Biochemistry 29: 4535-4540, 1990[Medline].
132. LINCK, B., P. BOKNÍK, T. ESCHENHAGEN, F. U. MÜLLER, J. NEUMANN, M. NOSE, L. R. JONES, W. SCHMITZ, AND H. SCHOLZ. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca2+-ATPase in failing and nonfailing human hearts. Cardiovasc. Res. 31: 625-632, 1996[Medline].
133.
LINDEMANN, J. P..
-Adrenergic stimulation of sarcolemmal protein phosphorylation and slow responses in intact myocardium.
J. Biol. Chem.
261: 4860-4867, 1986
134.
LINDEMANN, J. P.,
L. R. JONES,
D. R. HATHAWAY,
B. G. HENRY,
AND A. M. WATANABE.
-Adrenergic stimulation of phospholamban phosphorylation and Ca2+-ATPase activity in guinea pig ventricles.
J. Biol. Chem.
258: 464-471, 1983
135.
LINDEMANN, J. P.,
AND A. M. WATANABE.
Phosphorylation of phospholamban in intact myocardium: role of Ca2+-calmodulin-dependent mechanisms.
J. Biol. Chem.
260: 4516-4525, 1985
136.
LINDEMANN, J. P.,
AND A. M. WATANABE.
Muscarinic cholinergic inhibition of -adrenergic stimulation of phospholamban phosphorylation and Ca2+ transport in guinea pig ventricles.
J. Biol. Chem.
260: 13122-13129, 1985
136a.
LIU, Y.,
E. G. KRANIAS,
AND M. F. SCHNEIDER.
Regulation of Ca2+ handling by phosphorylation status in mouse fast- and slow-twitch skeletal muscle fibers.
Am. J. Physiol.
273(Cell Physiol. 42): C1915-C1924, 1997
137. LOMPRE, A.-M., M. ANGER, AND D. LEVITSKY. Sarco(endo)plasmic reticulum calcium pumps in the cardiovascular system: function and gene expression. J. Mol. Cell. Cardiol. 26: 1109-1121, 1994[Medline].
138. LOUIS, C. F., M. HOGAN, AND J. TURNQUIST. Properties of the 23,000-Da phosphoprotein in cardiac sarcolemma and sarcoplasmic reticulum. Arch. Biochem. Biophys. 246: 98-107, 1986[Medline].
139.
LOUIS, C. F.,
AND B. JARVIS.
Affinity labeling of calmodulin-binding components in canine cardiac sarcoplasmic reticulum.
J. Biol. Chem.
257: 15187-15191, 1982
140.
LOUIS, C. F.,
M. MOFFITT,
AND B. JARVIS.
Factors that modify the molecular size of phospholamban, the 23,000-dalton cardiac sarcoplasmic reticulum phosphoprotein.
J. Biol. Chem.
257: 15182-15186, 1982
141. LOUIS, C. F., J. TURNQUIST, AND B. JARVIS. Phospholamban stoichiometry in canine cardiac muscle sarcoplasmic reticulum. Neurochem. Res. 12: 937-941, 1987[Medline].
142. LU, Y.-Z., Z.-C. XU, AND M. A. KIRCHBERGER. Evidence for an effect of phospholamban on the regulatory role of ATP in calcium uptake by the calcium pump of the cardiac sarcoplasmic reticulum. Biochemistry 32: 3105-3111, 1993[Medline].
143. LUDLAM, C. F. C., I. T. ARKIN, X.-M. LIU, M. S. ROTHMAN, P. RATH, S. AIMOTO, S. O. SMITH, D. M. ENGELMAN, AND K. J. ROTHSCHILD. Fourier transform infrared spectroscopy and site-directed isotope labeling as a probe of local secondary structure in the transmembrane domain of phospholamban. Biophys. J. 70: 1728-1736, 1996[Medline].
144.
LUO, W.,
I. L. GRUPP,
J. HARRER,
S. PONNIAH,
G. GRUPP,
J. J. DUFFY,
T. DOETSCHMAN,
AND E. G. KRANIAS.
Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of -agonist stimulation.
Circ. Res.
75: 401-409, 1994
145. LUPAS, A.. Coiled coils: new structures and new functions. Trends Biochem. Sci. 21: 375-382, 1996[Medline].
146.
LYTTON, J.,
M. WESTLIN,
B. E. SCOTT,
G. E. SHULL,
AND D. H. MACLENNAN.
Functional comparisons between isoforms of the sarcoplasmic or endoplasmic reticulum family of calcium pumps.
J. Biol. Chem.
267: 14483-14489, 1992
147. MACDOUGALL, L. K., L. R. JONES, AND P. COHEN. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem. 196: 725-734, 1991[Medline].
148.
MAHONY, L.,
AND L. R. JONES.
Developmental changes in cardiac sarcoplasmic reticulum in sheep.
J. Biol. Chem.
261: 15257-15265, 1986
149. MALASHKEVICH, V. N., R. A. KAMMERER, V. P. EFIMOV, T. SCHULTHESS, AND J. ENGEL. The crystal structure of a five-stranded coiled coil in COMP: a prototype ion channel? Science 274: 761-765, 1996.
150.
MANALAN, A. S.,
AND L. R. JONES.
Characterization of the intrinsic cAMP-dependent protein kinase activity and endogenous substrates in highly purified cardiac sarcolemmal vesicles.
J. Biol. Chem.
257: 10052-10062, 1982
151. MASLENNIKOV, I. V., A. G. SOBOL, J. ANAGLI, P. JAMES, T. VORHERR, A. V. ARSENIEV, AND E. CARAFOLI. The secondary structure of phospholamban: a two dimensional study. Biochem. Biophys. Res. Commun. 217: 1200-1207, 1995[Medline].
152.
MAYER, E. J.,
E. MCKENNA,
V. M. GARSKY,
C. J. BURKE,
H. MACH,
C. R. MIDDAUGH,
M. SARDANA,
J. S. SMITH,
AND R. G. JOHNSON.
Biochemical and biophysical comparison of native and chemically synthesized phospholamban and a monomeric phospholamban analog.
J. Biol. Chem.
271: 1669-1677, 1996
153.
MEYER, M.,
W. SCHILLINGER,
B. PIESKE,
C. HOLUVARSCH,
C. HEILMANN,
H. POSIVAL,
G. KUWAJIMA,
K. MIKOSHIBA,
H. JUST,
AND G. HASENFUSS.
Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy.
Circulation
92: 778-784, 1995
154.
MCKENNA, E.,
J. S. SMITH,
K. E. COLL,
E. K. MAZACK,
E. J. MAYER,
J. ANTANAVAGE,
R. T. WIEDMANN,
AND R. G. JOHNSON.
JR. Dissociation of phospholamban regulation of cardiac sarcoplasmic reticulum Ca2+-ATPase by quercetin.
J. Biol. Chem.
271: 24517-24525, 1996
155.
MIYAKODA, G.,
A. YOSHIDA,
H. TAKISAWA,
AND T. NAKAMURA.
-Adrenergic regulation of contractility and protein phosphorylation in spontaneously beating isolated rat myocardial cells.
J. Biochem.
102: 211-224, 1987
156. MOLLA, A., J. P. CAPONY, AND J. G. DEMAILLE. Cardiac sarcoplasmic-reticulum calmodulin-binding proteins, modulation of calmodulin binding to phospholamban by phosphorylation. Biochem. J. 226: 859-865, 1985[Medline].
157.
MOORMAN, A. F. M.,
J. L. M. VERMEULEN,
M. U. KOBAN,
K. SCHWARTZ,
W. H. LAMERS,
AND K. R. BOHELER.
Patterns of expression of sarcoplasmic reticulum Ca2+-ATPase and phospholamban mRNAs during rat heart development.
Circ. Res.
76: 616-625, 1995
158. MORGAN, J. P.. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N. Engl. J. Med. 325: 625-632, 1991[Medline].
159.
MORRIS, G. L.,
H.-C. CHENG,
J. COLYER,
AND J. H. WANG.
Phospholamban regulation of cardiac sarcoplasmic reticulum (Ca2+-Mg2+)-ATPase: mechanism of regulation and site of monoclonal antibody interaction.
J. Biol. Chem.
266: 11270-11275, 1991
160. MORTISHIRE-SMITH, R. J., S. M. PITZENBERGER, C. J. BURKE, C. R. MIDDAUGH, V. M. GARSKY, AND R. G. JOHNSON. Solution structure of the cytoplasmic domain of phospholamban: phosphorylation leads to a local perturbation in secondary structure. Biochemistry 34: 7603-7613, 1995[Medline].
161. MOVSESIAN, M. A., J. COLYER, J. H. WANG, AND J. KRALL. Phospholamban-mediated stimulation of Ca2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J. Clin. Invest. 85: 1698-1702, 1990.
162.
MOVSESIAN, M. A.,
M. KARIMI,
K. GREEN,
AND L. R. JONES.
Ca2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium.
Circulation
90: 653-657, 1994
163.
MOVSESIAN, M. A.,
M. NISHIKAWA,
AND R. S. ADELSTEIN.
Phosphorylation of phospholamban by calcium-activated, phospholipid-dependent protein kinase.
J. Biol. Chem.
259: 8029-8032, 1984
164.
MUNDINA-WEILENMANN, C.,
L. VITTONE,
M. ORTALE,
G. C. DE CINGOLANI,
AND A. MATTIAZZI.
Immunodetection of phosphorylation sites give new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart.
J. Biol. Chem.
271: 33561-33567, 1996
165.
NAGAI, R.,
A. ZARAIN-HERZBERG,
C. J. BRANDL,
J. FUJII,
M. TADA,
D. H. MACLENNAN,
N. R. ALPERT,
AND M. PERIASAMY.
Regulation of myocardial Ca2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone.
Proc. Natl. Acad. Sci. USA
86: 2966-2970, 1989
166. NAPOLITANO, R., L. VITTONE, C. MUNDIÑA, G. C. DE CINGOLANI, AND A. MATTIAZZI. Phosphorylation of phospholamban in the intact heart. A study on the physiological role of the Ca2+-calmodulin-dependent protein kinase system. J. Mol. Cell. Cardiol. 24: 387-396, 1992[Medline].
167. NEGASH, S., L. T. CHEN, D. J. BIGELOW, AND T. C. SQUIER. Phosphorylation of phospholamban by cAMP-dependent protein kinase enhances interactions between Ca-ATPase polypeptide chains in cardiac sarcoplasmic reticulum membranes. Biochemistry 35: 11247-11259, 1996[Medline].
168. NEUMANN, J., P. BOKNIK, A. A. DEPAOLI-ROACH, L. J. FIELD, H. A. ROCKMAN, Y. M. KOBAYASHI, J. KELLEY, AND L. R. JONES. Targeted overexpression of phospholamban to mouse atrium depresses Ca2+ transport and contractility. J. Mol. Cell. Cardiol. In press.
169. NEUMANN, J., T. ESCHENHAGEN, L. R. JONES, B. LINCK, W. SCHMITZ, H. SCHHOZ, AND N. ZIMMERMAN. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell. Cardiol. 29: 265-272, 1997[Medline].
170.
NEUMANN, J.,
R. C. GUPTA,
W. SCHMITZ,
H. SCHOLZ,
A. C. NAIRN,
AND A. M. WATANABE.
Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart.
Circ. Res.
69: 1450-1457, 1991
171. NIMMO, H. G., AND P. COHEN. Hormonal control of protein phosphorylation. Adv. Cyclic Nucleotide Res. 8: 145-266, 1977[Medline].
172.
ODERMATT, A.,
K. KURZYDLOWSKI,
AND D. H. MACLENNAN.
The Vmax of the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) is not altered by Ca2+/calmodulin-dependent phosphorylation or by interaction with phospholamban.
J. Biol. Chem.
271: 14206-14213, 1996
172a. OTSU, K., M. PERIASAMY, M. DIFILIPPANTONIO, M. UPPENDER, D. C. WARD, AND D. H. MACLENNAN. Chromosome mapping of five human cardiac and skeletal muscle sarcoplasmic reticulum genes. Genomics 17: 507-509, 1993[Medline].
173. PALMER, C. J., B. T. SCOTT, AND L. R. JONES. Purification and complete sequence determination of the major plasma membrane substrate for cAMP-dependent protein kinase and protein kinase C in myocardium. J. Biol. Chem. 266: 11123-11130, 1991.
174. PLANK, B., C. PIFL, G. HELLMANN, W. WYSKOVSKY, R. HOFFMANN, AND J. SUKO. Correlation between calmodulin-dependent increase in the rate of calcium transport and calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulum. Eur. J. Biochem. 136: 215-221, 1983[Medline].
175.
PRESTI, C. F.,
L. R. JONES,
AND J. P. LINDEMANN.
Isoproterenol-induced phosphorylation of a 15-kDa sarcolemmal substrate in intact myocardium.
J. Biol. Chem.
260: 3860-3867, 1985
176.
PRESTI, C.,
B. T. SCOTT,
AND L. R. JONES.
Identification of an endogenous protein kinase C activity and its intrinsic 15-kilodalton substrate in purified canine cardiac sarcolemmal vesicles.
J. Biol. Chem.
260: 13879-13889, 1985
177. QUIRK, P. G., V. B. PATCHELL, J. COLYER, G. A. DRAGO, AND Y. GAO. Conformational effects of serine phosphorylation in phospholamban peptides. Eur. J. Biochem. 236: 85-91, 1996[Medline].
178. RAEYMAEKERS, L., J. A. EGGERMONT, F. WUYTACK, AND R. CASTEELS. Effects of cyclic nucleotide dependent protein kinases on the endoplasmic reticulum Ca2+ pump of bovine pulmonary artery. Cell Calcium 11: 261-268, 1990[Medline].
179. RAEYMAEKERS, L., F. HOFMANN, AND R. CASTEELS. Cyclic GMP-dependent protein kinase phosphorylates phospholamban in isolated sarcoplasmic reticulum from cardiac and smooth muscle. Biochem. J. 252: 269-273, 1988[Medline].
180. RAEYMAEKERS, L., AND L. R. JONES. Evidence for the presence of phospholamban in the endoplasmic reticulum of smooth muscle. Biochim. Biophys. Acta 882: 258-265, 1986[Medline].
181.
REDDY, L. G.,
L. R. JONES,
S. E. CALA,
J. J. O'BRIAN,
S. A. TATULIAN,
AND D. L. STOKES.
Functional reconstitution of recombinant phospholamban with rabbit skeletal Ca2+-ATPase.
J. Biol. Chem.
270: 9390-9397, 1995
182.
REDDY, L. G.,
L. R. JONES,
R. C. PACE,
AND D. L. STOKES.
Purified, reconstituted cardiac Ca2+-ATPase is regulated by phospholamban but not by direct phosphorylation with Ca2+/calmodulin-dependent protein kinase.
J. Biol. Chem.
271: 14964-14970, 1996
183. RINALDI, M. L., C. J. LEPEUCH, AND J. G. DEMAILLE. The epinephrine-induced activation of the cardiac slow Ca channel is mediated by the cAMP-dependent phosphorylation of calciductin, a 23,000 Mr sarcolemmal protein. FEBS Lett. 129: 277-281, 1981[Medline].
184.
ROCKMAN, H. A.,
S. ONO,
R. S. ROSS,
L. R. JONES,
M. KARIMI,
V. BHARGAVA,
AND J. ROSS.
JR., AND K. R. CHIEN. Molecular and physiological alterations in murine ventricular dysfunction.
Proc. Natl. Acad. Sci. USA
91: 2694-2698, 1994
185. SABINE, B., R. WILLENBROCK, H. HAASE, P. KARCZEWSKI, G. WALLUKAT, R. DIETZ, AND E.-G. KRAUSE. Cyclic GMP-mediated phospholamban phosphorylation in intact cardiomyocytes. Biochem. Biophys. Res. Commun. 214: 75-80, 1995[Medline].
186.
SARCEVIC, B.,
V. BROOKES,
T. J. MARTIN,
B. E. KEMP,
AND P. J. ROBINSON.
Atrial natriuretic peptide-dependent phosphorylation of smooth muscle cell particulate fraction proteins is mediated by cGMP-dependent protein kinase.
J. Biol. Chem.
264: 20648-20654, 1989
187.
SASAKI, T.,
M. INUI,
Y. KIMURA,
T. KUZUYA,
AND M. TADA.
Molecular mechanism of regulation of Ca2+ pump ATPase by phospholamban in cardiac sarcoplasmic reticulum: effects of synthetic phospholamban peptides on Ca2+ pump ATPase.
J. Biol. Chem.
267: 1674-1679, 1992
188.
SCHWINGER, R. H. G.,
M. BÖHM,
U. SCHMIDT,
P. KARCZEWSKI,
U. BAVENDIEK,
M. FLESCH,
R.-G. KRAUSE,
AND E. ERDMANN.
Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.
Circulation
92: 3220-3228, 1995
189.
SEILER, S.,
A. D. WEGENER,
D. D. WHANG,
D. R. HATHAWAY,
AND L. R. JONES.
High molecular weight proteins in cardiac and skeletal muscle junctional sarcoplasmic reticulum vesicles bind calmodulin, are phosphorylated, and are degraded by Ca2+-activated protease.
J. Biol. Chem.
259: 8550-8557, 1984
190.
SHAM, J. S. K.,
L. R. JONES,
AND M. MORAD.
Phospholamban mediates the -adrenergic-enhanced Ca2+ uptake in mammalian ventricular myocytes.
Am. J. Physiol.
261(Heart Circ. Physiol. 30): H1344-H1349, 1991
191. SHAMOO, A. E., I. S. AMBUDKAR, M. S. JACOBSON, AND J. BIDLACK. Regulation of calcium transport in cardiac sarcoplasmic reticulum. Curr. Top. Membr. Transp. 25: 131-145, 1985.
192. SHI, Y., B. S. KARON, H. KUTCHAI, AND D. D. THOMAS. Phospholamban-dependent effects of C12E8 on calcium transport and molecular dynamics in cardiac sarcoplasmic reticulum. Biochemistry 35: 13393-13399, 1996[Medline].
193.
SIMMERMAN, H. K. B.,
J. H. COLLINS,
J. L. THEIBERT,
A. D. WEGENER,
AND L. R. JONES.
Sequence analysis of phospholamban: identification of phosphorylation sites and two major structural domains.
J. Biol. Chem.
261: 13333-13341, 1986
194.
SIMMERMAN, H. K. B.,
Y. M. KOBAYASHI,
J. M. AUTRY,
AND L. R. JONES.
A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure.
J. Biol. Chem.
271: 5941-5946, 1996
195. SIMMERMAN, H. K. B., Y. M. KOBAYASHI, B. STRIFLER, AND L. R. JONES. Subunit interactions stabilizing the phospholamban pentamer (Abstract). Biophys. J. 66: A178, 1994.
196. SIMMERMAN, H. K. B., D. E. LOVELACE, AND L. R. JONES. Secondary structure of detergent-solubilized phospholamban, a phosphorylatable, oligomeric protein of cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 997: 322-329, 1989[Medline].
196a.
SLACK, J. P.,
I. L. GRUPP,
D. G. FERGUSON,
N. ROSENTHAL,
AND E. G. KRANIAS.
Ectopic expression of phospholamban in fast-twitch skeletal muscle alters sarcoplasmic reticulum Ca2+ transport and muscle relaxation.
J. Biol. Chem.
272: 18862-18868, 1997
196b.
SLACK, J. P.,
I. L. GRUPP,
W. LUO,
AND E. G. KRANIAS.
Phospholamban ablation enhances relaxation in the murine soleus.
Am. J. Physiol.
273(Cell Physiol. 42): C1-C6, 1997
197. STARLING, A. P., R. P. SHARMA, J. M. EAST, AND A. G. LEE. The effect of N-terminal acetylation on Ca2+-ATPase inhibition by phospholamban. Biochem. Biophys. Res. Commun. 226: 352-355, 1996[Medline].
197a. STOKES, D. L.. Keeping calcium in its place: Ca2+-ATPase and phospholamban. Curr. Opin. Struct. Biol. 7: 550-556, 1997[Medline].
198. STRASBURG, G. M., T. P. HANSON, H. X. OUYANG, AND C. F. LOUIS. Localization and functional role of the calmodulin-binding domain of phospholamban in cardiac sarcoplasmic reticulum vesicles. Biochim. Biophys. Acta 1149: 249-259, 1993[Medline].
199.
SUKO, J..
The calcium pump of cardiac sarcoplasmic reticulum. Functional alterations at different levels of thyroid state in rabbits.
J. Physiol. (Lond.)
228: 563-582, 1973
200. SULAKHE, P. V., AND X. T. VO. Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases, and depolarization. Mol. Cell. Biochem. 149-150: 103-126, 1995.
201. SUZUKI, T., P. LIU, AND J. H. WANG. Rapid purification of phospholamban by monoclonal antibody immunoaffinity chromatography. Biochem. Cell Biol. 65: 302-309, 1987[Medline].
202.
SUZUKI, T.,
AND J. H. WANG.
Stimulation of bovine cardiac sarcoplasmic reticulum Ca2+ pump and blocking of phospholamban phosphorylation and dephosphorylation by a phospholamban monoclonal antibody.
J. Biol. Chem.
261: 7018-7023, 1986
203.
SUZUKI, T.,
AND J. H. WANG.
The phosphorylation of purified phospholamban by cyclic AMP-dependent protein kinase is stimulated by phosphatidylinositol.
J. Biol. Chem.
262: 3880-3885, 1987
204.
SZYMANSKA, G.,
I. GRUPP,
J. P. SLACK,
J. M. HARRER,
AND E. G. KRANIAS.
Alterations in sarcoplasmic reticulum calcium uptake, relaxation parameters and their responses to -adrenergic agonists in the developing rabbit heart.
J. Mol. Cell. Cardiol.
27: 1819-1829, 1995[Medline].
205. SZYMANSKA, G., H. W. KIM, J. CUPPOLETTI, AND E. G. KRANIAS. Regulation of the skeletal sarcoplasmic reticulum Ca2+ pump by phospholamban in reconstituted phospholipid vesicles. Membr. Biochem. 9: 191-202, 1991.
206. SZYMANSKA, G., H. W. KIM, J. CUPPOLETTI, AND E. G. KRANIAS. Regulation of the skeletal sarcoplasmic reticulum Ca2+-ATPase by phospholamban and negatively charged phospholipids in reconstituted phospholipid vesicles. Mol. Cell. Biochem. 114: 65-71, 1992[Medline].
207. TADA, M.. Molecular structure and function of phospholamban in regulating the calcium pump from sarcoplasmic reticulum. Ann. NY Acad. Sci. 671: 92-102, 1992[Medline].
208. TADA, M., AND M. INUI. Regulation of calcium transport by the ATPase-phospholamban system. J. Mol. Cell. Cardiol. 15: 565-575, 1983[Medline].
209. TADA, M., M. INUI, M. YAMADA, M. KADOMA, T. KUZUYA, H. ABE, AND S. KAKICHI. Effects of phospholamban phosphorylation catalyzed by adenosine 3',5'-monophosphate and calmodulin-dependent protein kinases on calcium transport ATPase of cardiac sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 15: 335-346, 1983[Medline].
210. TADA, M., AND M. KADOMA. Regulation of the Ca2+ pump ATPase by cAMP-dependent phosphorylation of phospholamban. Bioessays 10: 157-163, 1989[Medline].
211. TADA, M., M., KADOMA, M. INUI, AND J. FUJII. Regulation of Ca2+ pump from cardiac sarcoplasmic reticulum. Methods Enzymol. 157: 107-154, 1988.
212. TADA, M., AND A. M. KATZ. Phosphorylation of the sarcoplasmic reticulum and sarcolemma. Annu. Rev. Physiol. 44: 401-423, 1982[Medline].
213.
TADA, M.,
M. A. KIRCHBERGER,
AND A. M. KATZ.
Phosphorylation of a 22,000-dalton component of the cardiac sarcoplasmic reticulum by adenosine 3',5'-monophosphate-dependent protein kinase.
J. Biol. Chem.
250: 2640-2647, 1975
214. TADA, M., M. A. KIRCHBERGER, AND H.-C. LI. Phosphoprotein phosphatase-catalyzed dephosphorylation of the 22,000 dalton phosphoprotein of cardiac sarcoplasmic reticulum. J. Cyclic Nucleotide Res. 1: 329-338, 1975[Medline].
215.
TADA, M.,
M. A. KIRCHBERGER,
D. I. REPKE,
AND A. M. KATZ.
The stimulation of calcium transport in cardiac sarcoplasmic reticulum by adenosine 3',5'-monophosphate-dependent protein kinase.
J. Biol. Chem.
249: 6174-6180, 1974
216. TADA, M., F. OHMORI, N. KINOSHITA, AND H. ABE. Cyclic AMP regulation of active calcium transport across membranes of sarcoplasmic reticulum: role of the 22,000-dalton protein phospholamban. Adv. Cyclic Nucleotide Res. 9: 355-369, 1978[Medline].
217. TADA, M., M. YAMADA, M. KADOMA, M. INUI, AND F. OHMORI. Calcium transport by cardiac sarcoplasmic reticulum and phosphorylation of phospholamban. Mol. Cell. Biochem. 46: 73-95, 1982[Medline].
218.
TADA, M.,
M. YAMADA,
F. OHMORI,
T. KUZUYA,
M. INUI,
AND H. ABE.
Transient state kinetic studies of Ca2+-dependent ATPase and calcium transport by cardiac sarcoplasmic reticulum: effect of cyclic AMP-dependent protein kinase-catalyzed phosphorylation of phospholamban.
J. Biol. Chem.
255: 1985-1992, 1980
219.
TALOSI, L.,
I. EDES,
AND E. KRANIAS.
Intracellular mechanisms mediating reversal of -adrenergic stimulation in intact beating hearts.
Am. J. Physiol.
264(Heart Circ. Physiol. 33): H791-H797, 1993
220. TATULIAN, S. A., L. R. JONES, L. G. REDDY, D. L. STOKES, AND L. K. TAMM. Secondary structure and orientation of phospholamban reconstituted in supported bilayers from polarized attenuated total reflection FTIR spectroscopy. Biochemistry 34: 4448-4456, 1995[Medline].
221. TERZI, E., L. POTEUR, AND E. TRIFILIEFF. Evidence for a phosphorylation-induced conformational change in phospholamban cytoplasmic domain by CD analysis. FEBS Lett. 309: 413-416, 1992[Medline].
222.
TOYOFUKU, T.,
D. D. DOYLE,
R. ZAK,
AND L. KORDYLEWSKI.
Expression of phospholamban mRNA during early avian muscle morphogenesis is distinct from that of -actin.
Dev. Dynamics
196: 103-113, 1993[Medline].
222a.
TOYOFUKU, T.,
K. KURZYDLOWSKI,
J. LYTTON,
AND D. H. MACLENNAN.
The nucleotide binding/hinge domain plays a crucial role in determining isoform-specific Ca2+ dependence of organellar Ca2+-ATPases.
J. Biol. Chem.
267: 14490-14496, 1992
223. TOYOFUKU, T., K. KURZYDLOWSKI, N. NARAYANAN, AND D. H. MACLennan. Identification of SER38 as the site in cardiac sarcoplasmic reticulum Ca2+-ATPase that is phosphorylated by Ca2+/calmodulin-dependent protein kinase. J. Biol. Chem. 269: 26492-26496, 1994.
224.
TOYOFUKU, T.,
K. KURZYDLOWSKI,
M. TADA,
AND D. H. MACLENNAN.
Identification of regions in the Ca2+-ATPase of sarcoplasmic reticulum that affect functional association with phospholamban.
J. Biol. Chem.
268: 2809-2815, 1993
225.
TOYOFUKU, T.,
K. KURZYDLOWSKI,
M. TADA,
AND D. H. MACLENNAN.
Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca2+-ATPase of sarcoplasmic reticulum.
J. Biol. Chem.
269: 3088-3094, 1994
226.
TOYOFUKU, T.,
K. KURZYDLOWSKI,
M. TADA,
AND D. H. MACLENNAN.
Amino acids Lys-Asp-Asp-Lys-Pro-Val402 in the Ca2+-ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban.
J. Biol. Chem.
269: 22929-22932, 1994
227.
TOYOFUKU, T.,
AND R. ZAK.
Characterization of cDNA and genomic sequences encoding a chicken phospholamban.
J. Biol. Chem.
266: 5375-5383, 1991
228. TSIEN, R. W.. Cyclic AMP and contractile activity in heart. Adv. Cyclic Nucleotide Res. 8: 363-420, 1977[Medline].
229.
UYEDA, A.,
K. KITANO,
J. FUJII,
M. KADOMA,
M. TADA,
AND S. TANAKA.
The cDNA sequence of the major phospholamban mRNA in canine cardiac ventricular muscle.
Nucleic Acids Res.
15: 6738, 1987
230. VERBOOMEN, H., F. WUYTACK, H. DE SMEDT, B. HIMPENS, AND R. CASTEELS. Functional difference between SERCA2a and SERCA2b Ca2+ pumps and their modulation by phospholamban. Biochem. J. 286: 591-595, 1992.
231. VERBOOMEN, H., F. WUYTACK, J. A. EGGERMONT, S. DE JAEGERE, L. MISSIAEN, L. RAEYMAEKERS, AND R. CASTEELS. cDNA cloning and sequencing of phospholamban from pig stomach smooth muscle. Biochem. J. 262: 353-356, 1989[Medline].
232.
VITTONE, L.,
C. MUNDIÑA,
G. C. DE CINGOLANI,
AND A. MATTIAZZI.
cAMP and calcium-dependent mechanisms of phospholamban phosphorylation in intact hearts.
Am. J. Physiol.
258(Heart Circ. Physiol. 27): H318-H325, 1990
233.
VITTONE, L.,
C. MUNDIÑA,
G. C. DE CINGOLANI,
AND A. MATTIAZZI.
Role of Ca2+-calmodulin dependent phospholamban phosphorylation on the relaxant effect of -adrenergic agonists.
Mol. Cell. Biochem.
124: 33-42, 1993[Medline].
234. VORHERR, T., M. CHIESI, R. SCHWALLER, AND E. CARAFOLI. Regulation of the calcium ion pump of sarcoplasmic reticulum: reversible inhibition by phospholamban and by the calmodulin binding domain of the plasma membrane calcium ion pump. Biochemistry 31: 371-376, 1992[Medline].
235. VORHERR, T., A. WRZOSEK, M. CHIESI, AND E. CARAFOLI. Total synthesis and functional properties of the membrane-intrinsic protein phospholamban. Protein Sci. 2: 339-347, 1993[Medline].
236. VOSS, J., L. R. JONES, AND D. D. THOMAS. The physical mechanism of calcium pump regulation in the heart. Biophys. J. 67: 190-196, 1994[Medline].
237. VOSS, J., J. E. MAHANEY, L. R. JONES, AND D. D. THOMAS. Molecular dynamics in mouse atrial tumor sarcoplasmic reticulum. Biophys. J. 68: 1787-1795, 1995[Medline].
238.
WATANABE, Y.,
Y. KIJIMA,
M. KADOMA,
M. TADA,
AND T. TAKAGI.
Molecular weight determination of phospholamban oligomer in the presence of sodium dodecyl sulfate: application of low-angle laser light scattering photometry.
J. Biochem.
110: 40-45, 1991
239. WATRAS, J.. Regulation of calcium uptake in bovine aortic sarcoplasmic reticulum by cyclic AMP-dependent protein kinase. J. Mol. Cell. Cardiol. 20: 711-723, 1988[Medline].
240.
WEGENER, A. D.,
AND L. R. JONES.
Phosphorylation-induced mobility shift in phospholamban in sodium dodecyl sulfate-polyacrylamide gels: evidence for a protein structure consisting of multiple identical phosphorylatable subunits.
J. Biol. Chem.
259: 1834-1841, 1984
241.
WEGENER, A. D.,
H. K. B. SIMMERMAN,
J. LIEPNIEKS,
AND L. R. JONES.
Proteolytic cleavage of phospholamban purified from canine cardiac sarcoplasmic reticulum vesicles: generation of a low resolution model of phospholamban structure.
J. Biol. Chem.
261: 5154-5159, 1986
242.
WEGENER, A. D.,
H. K. B. SIMMERMAN,
J. P. LINDEMANN,
AND L. R. JONES.
Phospholamban phosphorylation in intact ventricles: phosphorylation of serine 16 and threonine 17 in response to -adrenergic stimulation.
J. Biol. Chem.
264: 11468-11474, 1989
243. WEILENMANN, C. M.. DE, L. VITTONE, AND A. MATTIAZZI. Dissociation between contraction and relaxation: the possible role of phospholamban phosphorylation. Basic Res. Cardiol. 82: 507-516, 1987[Medline].
244. WILL, H., I. KÜTTNER, C. KEMSIES, R. VETTER, AND E. SCHUBERT. Comparative analysis of phospholamban phosphorylation in crude membranes of vertebrate hearts. Experientia 41: 1052-1054, 1985[Medline].
245. WILL, H., T. S. LEVCHENKO, D. O. LEVITSKY, V. N. SMIRNO, AND A. WOLLENBERGER. Partial characterization of protein kinase-catalyzed phosphorylation of low molecular weight proteins in purified preparations of pigeon heart sarcolemma and sarcoplasmic reticulum. Biochim. Biophys. Acta 543: 175-193, 1978[Medline].
245a.
WOLSKA, B. A.,
M. O. STOJANOVIC,
W. LUO,
E. G. KRANIAS,
AND R. J. SOLARO.
Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+.
Am. J. Physiol.
271(Cell Physiol. 40): C391-C397, 1996
246. WRAY, H. L., AND R. R. GRAY. Cyclic AMP stimulation of membrane phosphorylation and Ca2+-activated, Mg2+-dependent ATPase in cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 461: 441-459, 1977[Medline].
247. WRAY, H. L., R. R. GRAY, AND R. A OLSSON. Cyclic adenosine 3',5'-monophosphate-stimulated protein kinase and a substrate associated with cardiac sarcoplasmic reticulum. J. Biol. Chem. 248: 1496-1498, 1973.
248.
XIAO, R.-P.,
C. HOHL,
R. ALTSCHULD,
L. JONES,
B. LIVINGSTON,
B. ZIMAN,
B. TANTINI,
AND E. G. LAKATTA.
2-Adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation.
J. Biol. Chem.
269: 19151-19156, 1994
249.
XU, A.,
C. HAWKINS,
AND N. NARAYANAN.
Phosphorylation and activation of the Ca2+-pumping ATPase of cardiac sarcoplasmic reticulum by Ca2+/calmodulin-dependent protein kinase.
J. Biol. Chem.
268: 8394-8397, 1993
250.
XU, Z.-C.,
AND M. A. KIRCHBERGER.
Modulation by polyelectrolytes of canine cardiac microsomal calcium uptake and the possible relationship to phospholamban.
J. Biol. Chem.
264: 16644-16651, 1989
251. YOUNG, E. F., M. J. MCKEE, D. G. FERGUSON, AND E. G. KRANIAS. Structural characterization of phospholamban in cardiac sarcoplasmic reticulum membranes by cross-linking. Membr. Biochem. 8: 95-106, 1989[Medline].
252.
YOSHIDA, A.,
H. TAKISAWA,
AND T. NAKAMURA.
Bi-directional regulation of dephosphorylation of cAMP-dependent phosphorylated proteins by cAMP and calcium in permeabilized rat heart cells.
J. Biochem.
106: 894-899, 1989
This article has been cited by other articles:
|
|
 |
|
  N. J. Traaseth, L. Shi, R. Verardi, D. G. Mullen, G. Barany, and G. Veglia Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approach PNAS, June 23, 2009; 106(25): 10165 - 10170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fuller, J. Howie, L. M. McLatchie, R. J. Weber, C. J. Hastie, K. Burness, D. Pavlovic, and M. J. Shattock FXYD1 phosphorylation in vitro and in adult rat cardiac myocytes: threonine 69 is a novel substrate for protein kinase C Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1346 - C1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Waggoner, K. S. Ginsburg, B. Mitton, K. Haghighi, J. Robbins, D. M. Bers, and E. G. Kranias Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H698 - H703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vafiadaki, D. A. Arvanitis, S. N. Pagakis, V. Papalouka, D. Sanoudou, A. Kontrogianni-Konstantopoulos, and E. G. Kranias The Anti-apoptotic Protein HAX-1 Interacts with SERCA2 and Regulates Its Protein Levels to Promote Cell Survival Mol. Biol. Cell, January 1, 2009; 20(1): 306 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hou, E. M. Kelly, and S. L. Robia Phosphomimetic Mutations Increase Phospholamban Oligomerization and Alter the Structure of Its Regulatory Complex J. Biol. Chem., October 24, 2008; 283(43): 28996 - 29003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Kelly, Z. Hou, J. Bossuyt, D. M. Bers, and S. L. Robia Phospholamban Oligomerization, Quaternary Structure, and Sarco(endo)plasmic Reticulum Calcium ATPase Binding Measured by Fluorescence Resonance Energy Transfer in Living Cells J. Biol. Chem., May 2, 2008; 283(18): 12202 - 12211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sathish, F. Leblebici, S. N. Kip, M. A. Thompson, C. M. Pabelick, Y. S. Prakash, and G. C. Sieck Regulation of sarcoplasmic reticulum Ca2+ reuptake in porcine airway smooth muscle Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L787 - L796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Cheung Regulation of cardiac contractility: high time for FXYD Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H584 - H585. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Periasamy, P. Bhupathy, and G. J. Babu Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology Cardiovasc Res, January 15, 2008; 77(2): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Muthumala, F. Drenos, P. M. Elliott, and S. E. Humphries Role of {beta} adrenergic receptor polymorphisms in heart failure: Systematic review and meta-analysis Eur J Heart Fail, January 1, 2008; 10(1): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Ha, N. J. Traaseth, R. Verardi, J. Zamoon, A. Cembran, C. B. Karim, D. D. Thomas, and G. Veglia Controlling the Inhibition of the Sarcoplasmic Ca2+-ATPase by Tuning Phospholamban Structural Dynamics J. Biol. Chem., December 21, 2007; 282(51): 37205 - 37214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Avila, C. I. Aguilar, and R. Ramos-Mondragon Sustained CGRP1 receptor stimulation modulates development of EC coupling by cAMP/PKA signalling pathway in mouse skeletal myotubes J. Physiol., October 1, 2007; 584(1): 47 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Rose, C. Frosig, B. Kiens, J. F. P. Wojtaszewski, and E. A. Richter Effect of endurance exercise training on Ca2+ calmodulin-dependent protein kinase II expression and signalling in skeletal muscle of humans J. Physiol., September 1, 2007; 583(2): 785 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, B. L. Akin, and L. R. Jones Mechanism of Reversal of Phospholamban Inhibition of the Cardiac Ca2+-ATPase by Protein Kinase A and by Anti-phospholamban Monoclonal Antibody 2D12 J. Biol. Chem., July 20, 2007; 282(29): 20968 - 20976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Seddon, A. M. Shah, and B. Casadei Cardiomyocytes as effectors of nitric oxide signalling Cardiovasc Res, July 15, 2007; 75(2): 315 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kamishima, T. Burdyga, J. A. Gallagher, and J. M. Quayle Caveolin-1 and caveolin-3 regulate Ca2+ homeostasis of single smooth muscle cells from rat cerebral resistance arteries Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H204 - H214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Yeung, G. M. Kravtsov, K. M. Ng, T. M. Wong, and M. L. Fung Chronic intermittent hypoxia alters Ca2+ handling in rat cardiomyocytes by augmented Na+/Ca2+ exchange and ryanodine receptor activities in ischemia-reperfusion Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2046 - C2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pavlovic, W. Fuller, and M. J. Shattock The intracellular region of FXYD1 is sufficient to regulate cardiac Na/K ATPase FASEB J, May 1, 2007; 21(7): 1539 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jiang, A. Xu, and N. Narayanan Thyroid hormone downregulates the expression and function of sarcoplasmic reticulum-associated CaM kinase II in the rabbit heart Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1384 - H1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Rose, B. Kiens, and E. A. Richter Ca2+-calmodulin-dependent protein kinase expression and signalling in skeletal muscle during exercise J. Physiol., August 1, 2006; 574(3): 889 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-O. Larsen, I. Sjaastad, A. Svindland, K. A. Krobert, O. H. Skjonsberg, and G. Christensen Alveolar hypoxia induces left ventricular diastolic dysfunction and reduces phosphorylation of phospholamban in mice Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H507 - H516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Ranasinghe, C. J. McCabe, D. W. Quinn, S. R. James, D. Pagano, J. A. Franklyn, and R. S. Bonser How Does Glucose Insulin Potassium Improve Hemodynamic Performance?: Evidence for Altered Expression of Beta-Adrenoreceptor and Calcium Handling Genes Circulation, July 4, 2006; 114(1_suppl): I-239 - I-244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sathish, A. Xu, M. Karmazyn, S. M. Sims, and N. Narayanan Mechanistic basis of differences in Ca2+-handling properties of sarcoplasmic reticulum in right and left ventricles of normal rat myocardium Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H88 - H96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, B. L. Akin, D. L. Stokes, and L. R. Jones Cross-linking of C-terminal Residues of Phospholamban to the Ca2+ Pump of Cardiac Sarcoplasmic Reticulum to Probe Spatial and Functional Interactions within the Transmembrane Domain J. Biol. Chem., May 19, 2006; 281(20): 14163 - 14172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Abdallah, A. Gkatzoflia, D. Gligorievski, S. Kasseckert, G. Euler, K.-D. Schluter, M. Schafer, H.-M. Piper, and C. Schafer Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage Cardiovasc Res, May 1, 2006; 70(2): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Zhang, B. A. Ahlers, A. L. Tucker, J. Song, J. Wang, J. R. Moorman, J. P. Mounsey, L. L. Carl, L. I. Rothblum, and J. Y. Cheung Phospholemman Inhibition of the Cardiac Na+/Ca2+ Exchanger: ROLE OF PHOSPHORYLATION J. Biol. Chem., March 24, 2006; 281(12): 7784 - 7792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Gramolini, M. G. Trivieri, G. Y. Oudit, T. Kislinger, W. Li, M. M. Patel, A. Emili, E. G. Kranias, P. H. Backx, and D. H. MacLennan Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation PNAS, February 14, 2006; 103(7): 2446 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lindegger and E. Niggli Paradoxical SR Ca2+ release in guinea-pig cardiac myocytes after {beta}-adrenergic stimulation revealed by two-photon photolysis of caged Ca2+ J. Physiol., June 15, 2005; 565(3): 801 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Song, X.-Q. Zhang, B. A. Ahlers, L. L. Carl, J. Wang, L. I. Rothblum, R. C. Stahl, J. P. Mounsey, A. L. Tucker, J. R. Moorman, et al. Serine 68 of phospholemman is critical in modulation of contractility, [Ca2+]i transients, and Na+/Ca2+ exchange in adult rat cardiac myocytes Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2342 - H2354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Abdallah, A. Gkatzoflia, H. Pieper, E. Zoga, S. Walther, S. Kasseckert, M. Schafer, K.D. Schluter, H.M. Piper, and C. Schafer Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury Cardiovasc Res, April 1, 2005; 66(1): 123 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-G. Jia, C. Donnet, R. C. Bogaev, R. J. Blatt, C. E. McKinney, K. H. Day, S. S. Berr, L. R. Jones, J. R. Moorman, K. J. Sweadner, et al. Hypertrophy, increased ejection fraction, and reduced Na-K-ATPase activity in phospholemman-deficient mice Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1982 - H1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zamoon, F. Nitu, C. Karim, D. D. Thomas, and G. Veglia Mapping the interaction surface of a membrane protein: Unveiling the conformational switch of phospholamban in calcium pump regulation PNAS, March 29, 2005; 102(13): 4747 - 4752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, D. L. Stokes, and L. R. Jones Role of Leucine 31 of Phospholamban in Structural and Functional Interactions with the Ca2+ Pump of Cardiac Sarcoplasmic Reticulum J. Biol. Chem., March 18, 2005; 280(11): 10530 - 10539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. U. Muller, G. Lewin, H. A. Baba, P. Boknik, L. Fabritz, U. Kirchhefer, P. Kirchhof, K. Loser, M. Matus, J. Neumann, et al. Heart-directed Expression of a Human Cardiac Isoform of cAMP-Response Element Modulator in Transgenic Mice J. Biol. Chem., February 25, 2005; 280(8): 6906 - 6914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Babu, Z. Zheng, P. Natarajan, D. Wheeler, P. M. Janssen, and M. Periasamy Overexpression of sarcolipin decreases myocyte contractility and calcium transient Cardiovasc Res, January 1, 2005; 65(1): 177 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Gramolini, T. Kislinger, M. Asahi, W. Li, A. Emili, and D. H. MacLennan Sarcolipin retention in the endoplasmic reticulum depends on its C-terminal RSYQY sequence and its interaction with sarco(endo)plasmic Ca2+-ATPases PNAS, November 30, 2004; 101(48): 16807 - 16812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, W. Zhu, S. Wang, D. Yang, M. T. Crow, R.-P. Xiao, and H. Cheng Sustained {beta}1-Adrenergic Stimulation Modulates Cardiac Contractility by Ca2+/Calmodulin Kinase Signaling Pathway Circ. Res., October 15, 2004; 95(8): 798 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Karim, T. L. Kirby, Z. Zhang, Y. Nesmelov, and D. D. Thomas Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly coupled to the peptide backbone PNAS, October 5, 2004; 101(40): 14437 - 14442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Gergs, P. Boknik, I. Buchwalow, L. Fabritz, M. Matus, I. Justus, G. Hanske, W. Schmitz, and J. Neumann Overexpression of the Catalytic Subunit of Protein Phosphatase 2A Impairs Cardiac Function J. Biol. Chem., September 24, 2004; 279(39): 40827 - 40834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jiang, A. Xu, D.L. Jones, and N. Narayanan Coordinate downregulation of CaM kinase II and phospholamban accompanies contractile phenotype transition in the hyperthyroid rabbit soleus Am J Physiol Cell Physiol, September 1, 2004; 287(3): C622 - C632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kirchhefer, L. R Jones, F. Begrow, P. Boknik, L. Hein, M. J Lohse, B. Riemann, W. Schmitz, J. Stypmann, and J. Neumann Transgenic triadin 1 overexpression alters SR Ca2+ handling and leads to a blunted contractile response to {beta}-adrenergic agonists Cardiovasc Res, April 1, 2004; 62(1): 122 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Engelhardt, L. Hein, V. Dyachenkow, E. G. Kranias, G. Isenberg, and M. J. Lohse Altered Calcium Handling Is Critically Involved in the Cardiotoxic Effects of Chronic {beta}-Adrenergic Stimulation Circulation, March 9, 2004; 109(9): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Bidasee, Y. Zhang, C. H. Shao, M. Wang, K. P. Patel, U. D. Dincer, and H. R. Besch Diabetes Increases Formation of Advanced Glycation End Products on Sarco(endo)plasmic Reticulum Ca2+-ATPase Diabetes, February 1, 2004; 53(2): 463 - 473. [Abstract] [Full Text]
|
|
|
|
|
|
M. Stange, L. Xu, D. Balshaw, N. Yamaguchi, and G. Meissner Characterization of Recombinant Skeletal Muscle (Ser-2843) and Cardiac Muscle (Ser-2809) Ryanodine Receptor Phosphorylation Mutants J. Biol. Chem., December 19, 2003; 278(51): 51693 - 51702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Neumann, P. Boknik, F. Begrow, G. Hanske, I. Justus, M. Mat'us, U. Reinke, G.P. Matherne, and W. Schmitz Altered signal transduction in cardiac ventricle overexpressing A1-adenosine receptors Cardiovasc Res, December 1, 2003; 60(3): 529 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, D. L. Stokes, W. J. Rice, and L. R. Jones Spatial and Dynamic Interactions between Phospholamban and the Canine Cardiac Ca2+ Pump Revealed with Use of Heterobifunctional Cross-linking Agents J. Biol. Chem., November 28, 2003; 278(48): 48348 - 48356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Rose and M. Hargreaves Exercise increases Ca2+-calmodulin-dependent protein kinase II activity in human skeletal muscle J. Physiol., November 15, 2003; 553(1): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Terentyev, S. Viatchenko-Karpinski, I. Gyorke, R. Terentyeva, and S. Gyorke Protein Phosphatases Decrease Sarcoplasmic Reticulum Calcium Content by Stimulating Calcium Release in Cardiac Myocytes J. Physiol., October 1, 2003; 552(1): 109 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Cao, Q. Xia, I. C. Bruce, X. Zhang, C. Fu, and J.-Z. Chen Interleukin-2 Increases Activity of Sarcoplasmic Reticulum Ca2+-ATPase, but Decreases Its Sensitivity to Calcium in Rat Cardiomyocytes J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. White and J. G. McGeown Inositol 1,4,5-trisphosphate receptors modulate Ca2+ sparks and Ca2+ store content in vas deferens myocytes Am J Physiol Cell Physiol, July 1, 2003; 285(1): C195 - C204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Grey, C. K. Chan, Y. Chen, and P. A. Hofmann Age-related functional effects linked to phosphatase activity in ventricular myocytes Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H90 - H96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hughes and D. A. Middleton Solid-state NMR Reveals Structural Changes in Phospholamban Accompanying the Functional Regulation of Ca2+-ATPase J. Biol. Chem., May 30, 2003; 278(23): 20835 - 20842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Antoons, M. Ver Heyen, L. Raeymaekers, P. Vangheluwe, F. Wuytack, and K. R. Sipido Ca2+ Uptake by the Sarcoplasmic Reticulum in Ventricular Myocytes of the SERCA2b/b Mouse Is Impaired at Higher Ca2+ Loads Only Circ. Res., May 2, 2003; 92(8): 881 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Asahi, Y. Sugita, K. Kurzydlowski, S. De Leon, M. Tada, C. Toyoshima, and D. H. MacLennan Sarcolipin regulates sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban PNAS, April 29, 2003; 100(9): 5040 - 5045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Pall, K. J. Johnson, and G. L. Smith Abnormal contractile activity and calcium cycling in cardiac myocytes isolated from dmpk knockout mice Physiol Genomics, April 16, 2003; 13(2): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yang, L.-S. Song, W.-Z. Zhu, K. Chakir, W. Wang, C. Wu, Y. Wang, R.-P. Xiao, S.R. W. Chen, and H. Cheng Calmodulin Regulation of Excitation-Contraction Coupling in Cardiac Myocytes Circ. Res., April 4, 2003; 92(6): 659 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Feschenko, C. Donnet, R. K. Wetzel, N. K. Asinovski, L. R. Jones, and K. J. Sweadner Phospholemman, a Single-Span Membrane Protein, Is an Accessory Protein of Na,K-ATPase in Cerebellum and Choroid Plexus J. Neurosci., March 15, 2003; 23(6): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Guo and H J Duff Inactivation of ICa-L is the major determinant of use-dependent facilitation in rat cardiomyocytes J. Physiol., March 15, 2003; 547(3): 797 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Schertzer, H. J. Green, T. A. Duhamel, and A. R. Tupling Mechanisms underlying increases in SR Ca2+-ATPase activity after exercise in rat skeletal muscle Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E597 - E610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Toyoshima, M. Asahi, Y. Sugita, R. Khanna, T. Tsuda, and D. H. MacLennan Inaugural Article: Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase PNAS, January 21, 2003; 100(2): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Tupling, M. Asahi, and D. H. MacLennan Sarcolipin Overexpression in Rat Slow Twitch Muscle Inhibits Sarcoplasmic Reticulum Ca2+ Uptake and Impairs Contractile Function J. Biol. Chem., November 15, 2002; 277(47): 44740 - 44746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Lorenz, M. H. Riddervold, E. A. H. Beckett, S. A. Baker, and B. A. Perrino Differential autophosphorylation of CaM kinase II from phasic and tonic smooth muscle tissues Am J Physiol Cell Physiol, November 1, 2002; 283(5): C1399 - C1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wechsler, Y.-H. Choi, J. Krall, F. Ahmad, V. C. Manganiello, and M. A. Movsesian Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3A in Cardiac Myocytes J. Biol. Chem., October 4, 2002; 277(41): 38072 - 38078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, V. Piacentino III, S. Furukawa, B. Goldman, K. B. Margulies, and S. R. Houser L-Type Ca2+ Channel Density and Regulation Are Altered in Failing Human Ventricular Myocytes and Recover After Support With Mechanical Assist Devices Circ. Res., September 20, 2002; 91(6): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Huke, V. Prasad, M. L. Nieman, K. J. Nattamai, I. L. Grupp, J. N. Lorenz, and M. Periasamy Altered dose response to beta -agonists in SERCA1a-expressing hearts ex vivo and in vivo Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H958 - H965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T Gewaltig and G. Kojda Vasoprotection by nitric oxide: mechanisms and therapeutic potential Cardiovasc Res, August 1, 2002; 55(2): 250 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Jones, R. L. Cornea, and Z. Chen Close Proximity between Residue 30 of Phospholamban and Cysteine 318 of the Cardiac Ca2+ Pump Revealed by Intermolecular Thiol Cross-linking J. Biol. Chem., July 26, 2002; 277(31): 28319 - 28329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Howard, J. D. Lear, and W. F. DeGrado Sequence determinants of the energetics of folding of a transmembrane four-helix-bundle protein PNAS, June 25, 2002; 99(13): 8568 - 8572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Carr, A. G. Schmidt, Y. Suzuki, F. del Monte, Y. Sato, C. Lanner, K. Breeden, S.-L. Jing, P. B. Allen, P. Greengard, et al. Type 1 Phosphatase, a Negative Regulator of Cardiac Function Mol. Cell. Biol., June 15, 2002; 22(12): 4124 - 4135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Salaun, E. Gyan, P. Rodrigues, and J. M. Heard Pit2 Assemblies at the Cell Surface Are Modulated by Extracellular Inorganic Phosphate Concentration J. Virol., March 27, 2002; 76(9): 4304 - 4311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kimura and M. Inui Reconstitution of the Cytoplasmic Interaction between Phospholamban and Ca2+-ATPase of Cardiac Sarcoplasmic Reticulum Mol. Pharmacol., March 1, 2002; 61(3): 667 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, E. G. Kranias, G. A. Mignery, and D. M. Bers Protein Kinase A Phosphorylation of the Ryanodine Receptor Does Not Affect Calcium Sparks in Mouse Ventricular Myocytes Circ. Res., February 22, 2002; 90(3): 309 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Wellman, L. F. Santana, A. D. Bonev, and M. T. Nelson Role of phospholamban in the modulation of arterial Ca2+ sparks and Ca2+-activated K+ channels by cAMP Am J Physiol Cell Physiol, September 1, 2001; 281(3): C1029 - C1037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boknik, I. Heinroth-Hoffmann, U. Kirchhefer, J. Knapp, B. Linck, H. Luss, T. Muller, W. Schmitz, O.-E. Brodde, and J. Neumann Enhanced protein phosphorylation in hypertensive hypertrophy Cardiovasc Res, September 1, 2001; 51(4): 717 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Asahi, N. M. Green, K. Kurzydlowski, M. Tada, and D. H. MacLennan Phospholamban domain IB forms an interaction site with the loop between transmembrane helices M6 and M7 of sarco(endo)plasmic reticulum Ca2+ ATPases PNAS, August 28, 2001; 98(18): 10061 - 10066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rymer, S. S. Miller, and J. L. Edelman Epinephrine-Induced Increases in [Ca2+]in and KCl-Coupled Fluid Absorption in Bovine RPE Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1921 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dittrich, J. Jurevicius, M. Georget, F. Rochais, B. K. Fleischmann, J. Hescheler, and R. Fischmeister Local response of L-type Ca2+ current to nitric oxide in frog ventricular myocytes J. Physiol., July 1, 2001; 534(1): 109 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Rao, A. Xu, and N. Narayanan Glucocorticoid modulation of protein phosphorylation and sarcoplasmic reticulum function in rat myocardium Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H325 - H333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boknik, S. Khorchidi, G. S. Bodor, S. Huke, J. Knapp, B. Linck, H. Luss, F. U. Muller, W. Schmitz, and J. Neumann Role of protein phosphatases in regulation of cardiac inotropy and relaxation Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H786 - H794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Quinn, J. N. Quong, and S. S. Miller Adrenergic Receptor Activated Ion Transport in Human Fetal Retinal Pigment Epithelium Invest. Ophthalmol. Vis. Sci., January 1, 2001; 42(1): 255 - 264. [Abstract] [Full Text]
|
|
|
|
|
|
J.-M. Goaillard, P. Vincent, and R. Fischmeister Simultaneous measurements of intracellular cAMP and L-type Ca2+ current in single frog ventricular myocytes J. Physiol., January 1, 2001; 530(1): 79 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Knapp, P. Bokník, B. Linck, H. Lüss, F. U. Müller, L. Petertönjes, W. Schmitz, and J. Neumann Cantharidin Enhances Norepinephrine-Induced Vasoconstriction in an Endothelium-Dependent Fashion J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 620 - 626. [Abstract] [Full Text]
|
|
|
|
 |
|
 L.-Q. Zhang, X.-Q. Zhang, Y.-C. Ng, L. I. Rothblum, T. I. Musch, R. L. Moore, and J. Y. Cheung Sprint training normalizes Ca2+ transients and SR function in postinfarction rat myocytes J Appl Physiol, July 1, 2000; 89(1): 38 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Berchtold, H. Brinkmeier, and M. Muntener Calcium Ion in Skeletal Muscle: Its Crucial Role for Muscle Function, Plasticity, and Disease Physiol Rev, July 1, 2000; 80(3): 1215 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zvaritch, P. H. Backx, F. Jirik, Y. Kimura, S. de Leon, A. G. Schmidt, B. D. Hoit, J. W. Lester, E. G. Kranias, and D. H. MacLennan The Transgenic Expression of Highly Inhibitory Monomeric Forms of Phospholamban in Mouse Heart Impairs Cardiac Contractility J. Biol. Chem., May 12, 2000; 275(20): 14985 - 14991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Asahi, E. McKenna, K. Kurzydlowski, M. Tada, and D. H. MacLennan Physical Interactions between Phospholamban and Sarco(endo)plasmic Reticulum Ca2+-ATPases Are Dissociated by Elevated Ca2+, but Not by Phospholamban Phosphorylation, Vanadate, or Thapsigargin, and Are Enhanced by ATP J. Biol. Chem., May 12, 2000; 275(20): 15034 - 15038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Eizema, H. Fechner, K. Bezstarosti, S. Schneider-Rasp, A. van der Laarse, H. Wang, H.-P. Schultheiss, W. C. Poller, and J. M. J. Lamers Adenovirus-Based Phospholamban Antisense Expression as a Novel Approach to Improve Cardiac Contractile Dysfunction : Comparison of a Constitutive Viral Versus an Endothelin-1-Responsive Cardiac Promoter Circulation, May 9, 2000; 101(18): 2193 - 2199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Brittsan, A. N. Carr, A. G. Schmidt, and E. G. Kranias Maximal Inhibition of SERCA2 Ca2+ Affinity by Phospholamban in Transgenic Hearts Overexpressing a Non-phosphorylatable Form of Phospholamban J. Biol. Chem., April 14, 2000; 275(16): 12129 - 12135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhai, A. G. Schmidt, B. D. Hoit, Y. Kimura, D. H. MacLennan, and E. G. Kranias Cardiac-specific Overexpression of a Superinhibitory Pentameric Phospholamban Mutant Enhances Inhibition of Cardiac Function in Vivo J. Biol. Chem., March 31, 2000; 275(14): 10538 - 10544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Xu and N. Narayanan Reversible Inhibition of the Calcium-pumping ATPase in Native Cardiac Sarcoplasmic Reticulum by a Calmodulin-binding Peptide. EVIDENCE FOR CALMODULIN-DEPENDENT REGULATION OF THE Vmax OF CALCIUM TRANSPORT J. Biol. Chem., February 11, 2000; 275(6): 4407 - 4416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U Ravens and D Dobrev Regulation of sarcoplasmic reticulum Ca2+-ATPase and phospholamban in the failing and nonfailing heart Cardiovasc Res, January 1, 2000; 45(1): 245 - 252. [Full Text] [PDF]
|
|
|
|
|
|
M. Ga{beta}el, T. Mollenkamp, W. Puppe, and K. Altendorf The KdpF Subunit Is Part of the K+-translocating Kdp Complex of Escherichia coli and Is Responsible for Stabilization of the Complex in Vitro J. Biol. Chem., December 31, 1999; 274(53): 37901 - 37907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Asahi, Y. Kimura, K. Kurzydlowski, M. Tada, and D. H. MacLennan Transmembrane Helix M6 in Sarco(endo)plasmic Reticulum Ca2+-ATPase Forms a Functional Interaction Site with Phospholamban. EVIDENCE FOR PHYSICAL INTERACTIONS AT OTHER SITES J. Biol. Chem., November 12, 1999; 274(46): 32855 - 32862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boknik, C. Unkel, U. Kirchhefer, U. Kleideiter, O. Klein-Wiele, J. Knapp, B. Linck, H. Luss, F. Ulrich Muller, W. Schmitz, et al. Regional expression of phospholamban in the human heart Cardiovasc Res, July 1, 1999; 43(1): 67 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Neumann, R. Maas, P. Bokník, L. R. Jones, N. Zimmermann, and H. Scholz Pharmacological Characterization of Protein Phosphatase Activities in Preparations from Failing Human Hearts J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 188 - 193. [Abstract] [Full Text]
|
|
|
|
|
|
L. G. Reddy, J. M. Autry, L. R. Jones, and D. D. Thomas Co-reconstitution of Phospholamban Mutants with the Ca-ATPase Reveals Dependence of Inhibitory Function on Phospholamban Structure J. Biol. Chem., March 19, 1999; 274(12): 7649 - 7655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hagemann, M. Kuschel, T. Kuramochi, W. Zhu, H. Cheng, and R.-P. Xiao Frequency-encoding Thr17 Phospholamban Phosphorylation Is Independent of Ser16 Phosphorylation in Cardiac Myocytes J. Biol. Chem., July 14, 2000; 275(29): 22532 - 22536. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
